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Colorectal cancer (CRC) is the third leading cause of cancer related deaths 
worldwide. Cancer cells modify normal cell functions to adapt to the surrounding tumor 
microenvironment. Autophagy is a basic cell function used to degrade organelles, 
aggregated proteins, and nutrients to recycle for cellular use. In cancer, autophagy is 
known to play both tumor promoting and suppressive roles. In colon cancer, autophagy 
can enhance or inhibit tumor growth and the function is often tumor stage and context 
dependent. A more in-depth understanding of how autophagy alters tumor growth is 
necessary to better develop treatments for patients with colon cancer.  
 Previous literature has shown a cross-talk between epithelial autophagy and the 
intestinal immune response. This dissertation uncovers a novel cell-autonomous role for 
autophagy in colon cancer independent of the immune system. While autophagy is 
classically known to provide nutrients to the cell, the cellular components that are targeted 
for breakdown and under what context they are targeted is not known in colon cancer. 
Tumor cell growth is inhibited following autophagy loss, but normal colon epithelia are not 
impacted by inhibition suggesting a tumor selective reliance on autophagy. Under nutrient 
stress tumor cells employ mitophagy, a selective form of autophagy that targets 
mitochondria for breakdown. Inhibition of PINK/PRKN directed mitophagy significantly 
reduces cell growth.  
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Lastly, I assessed cell type specificity of autophagy in CRC. Autophagy is known 
to have differential roles in epithelial sub-types. In inflammatory bowel disease, loss of 
autophagy specifically alters Paneth cell function. To explore the role of autophagy in 
colon cancer, I utilized single-cell RNA sequencing to investigate changes in autophagy 
in epithelial cells in colon cancer. In a sporadic tumor model with loss of Apc, p53, and 
KrasG12D I performed single-cell analysis on colon tissue. I found that enterocytes express 
genes associated with increased autophagy in comparison to goblet cells or 
enteroendocrine cells. This data suggests a specific increase in autophagy in tumor 
enterocytes. Further single-cell analysis at different stages of tumor development and 
focus on different cell types will begin to uncover how colon tumors are modulated by 
autophagy.  
This dissertation uncovers the cell type specificity and cell-autonomous role for 
autophagy in colon cancer. Further in-depth studies are needed to assess the role of 
tumor stage and mutational load in the requirement of autophagy in colon cancer. I have 
identified that tumor cells rely on mitophagy for growth and lay the foundation for therapies 













Colorectal cancer (CRC) is the third leading cause of cancer related deaths in the 
United States. It is estimated that in 2018 over 140,000 people were diagnosed with CRC 
[1]. Survival rates have improved in the last three decades due to early detection, however 
patients diagnosed at later stages of disease have a 5-year survival rate of 14% [2, 3]. 
Treatments available for these patients are limited, therefore it is important to better 
understand tumor development and identify targeted therapies to improve overall patient 
care. Sporadic CRCs are typically marked by the initial loss of the adenomatous polyposis 
coli (APC) gene. APC is a scaffold protein that leads to proteasomal degradation of β-
catenin. Under active cell states, WNT ligands bind to its receptor frizzled and prevent β-
catenin degradation and activate target genes. Loss of APC constitutively activates β-
catenin and causes uncontrolled epithelial proliferation. Mutations in APC are typically 
followed by sequential mutations in tumor protein p53 (p53), and mutations in KRAS 
leading to spontaneous tumor development and progression [4]. It is well known that 
chronic inflammatory diseases such as Crohn’s Disease or ulcerative colitis increase risk 
of developing colon cancer, referred to as colitis-associated cancer (CAC) [5, 6]. CACs 
developed from inflammatory bowel diseases (IBD) are a rare subset. Moreover, p53 
                                                 
1  This chapter represents a publish manuscript.  Devenport SN and Shah YM. Functions and 
Implications of Autophagy in Colon Cancer. Cells 8(11) Oct 30, 2019.  
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mutations occur earlier in the progression of CAC and APC mutations are less frequent 
and are found in late stage tumors in comparison to sporadic CRC [7]. However, CAC 
provides a clear link between inflammation and tumor initiation.  
Autophagy is a highly regulated process that degrades and recycles cellular 
components. Dysregulation of autophagy is implicated in many diseases (as reviewed in 
[8]). Under several different cell stressors, autophagy is activated through kinase 
signaling and transcriptional activation by serine/threonine protein kinase 1 (ULK1) and 
transcription factor EB (TFEB). This activates a cascade of autophagy-related genes 
(ATG) [9], and formation of a spherical double layer membrane termed the 
autophagosome. The autophagosome delivers key cytoplasmic cargo such as 
organelles, foreign bodies, and cellular components to the lysosome for degradation into 
macromolecules that can be utilized by the cell. In CRC, autophagy is known to play tumor 
promoting and tumor suppressive roles [10, 11], but the underlying mechanisms are not 
well understood. Studies have found conflicting functions of autophagy in tumors. These 
discrepancies are typically due to differences in the cells and tumor models that are 
utilized [12-15]. Further study of autophagy and its prevalence in CRC will uncover its 
potential therapeutic use [16]. Here we highlight cellular pathways that regulate 
autophagy, selective forms of autophagy, and how these mechanisms target different 
cargo for degradation.    
2. Autophagy subtypes 
Autophagy can be classified into three major subtypes; macro-autophagy, micro-
autophagy, and chaperone-mediated autophagy. There is a need for better 
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understanding of cellular cues and cell-dependent context by which autophagic subtypes 
are co-opted in cancer cells for growth and survival.  
Chaperone-mediated autophagy 
Chaperone-mediated autophagy (CMA) differs from macro-autophagy in that select 
proteins are targeted for degradation by direct targeting to the lysosome. Proteins are 
recognized by heat shock cognate protein 70 (HSC70). HSC70 interacts with lysosome-
associated membrane protein type 2A (LAMP-2A) to internalize proteins into the 
lysosome. CMA substrates contain a specific motif, KFERQ, which is essential for HSC70 
binding [17]. Relevant to cancer, inhibition of macro-autophagy enhances CMA-
dependent degradation of mutant p53 [18]. Increased expression of LAMP-2A 
demonstrated activated CMA in CRC [19]. These functions highlight a potential role of 
CMA in tumor development. However, these processes have not been well studied in 
CRC.  
Micro-autophagy 
 Micro-autophagy is the direct engulfment of cellular components by invagination 
of the late endosome (Figure 1.1). Broadly, the implications of micro-autophagy have not 
been studied in many cancer types. There is evidence in lung cancer that amino acid 
starvation, an important factor in cancer growth (discussed below), induces micro-
autophagy [20]. However, the role of micro-autophagy in CRC has not been investigated 






Macro-autophagy can be broken down in to two subcategories that target cellular 
components for degradation; non-selective and selective. Non-selective macro-
autophagy engulfs bulk cytosolic components and selective autophagy targets specific 
cargo for degradation (e.g. organelles and protein aggregates). For macro-autophagy, 
the phagophore, a precursor to the autophagosome, forms. Several ATG protein 
complexes are involved in early and late autophagosome formation [21]. . As the 
membrane is forming, microtubule associated protein 1 light chain 3 beta (LC3-I) is 
conjugated with phosphatidylethanolamine and is processed into LC3-II [22]. Following 
fusion of the autophagosome with the lysosome, which contains the required enzymes 
for cargo degradation, LC3-II is broken down by the lysosome [23]. The turnover of LC3-
II is often used as a readout of autophagic activity [24]. Here we have provided a highly 
simplified overview of the complex process of macro-autophagy. This extremely 
coordinated event of cytoplasmic engulfment is generally activated in states of cell stress 
such as starvation. Anding and Baehrecke review the important role of selective-
autophagic processes in maintaining cellular homeostasis in response to stress [25]. 
Below we highlight the known selective-autophagic pathways and their potential role in 
CRC (Figure 1.1). 
Mitophagy 
Mitophagy is a process that selectively degrades mitochondria [26-29]. Mitophagy is 
highly evolutionarily conserved [30] and is known to be activated in yeast under starvation 
[31]. Therefore, highly proliferative cells under nutrient stress and starvation, such as 
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cancer cells, may activate mitophagy. This process can be modulated by different 
pathways as discussed below.  
 
Parkin-mediated mitophagy  
Under normal cell homeostasis, PTEN induced kinase 1 (PINK1) is maintained on 
the inner mitochondrial membrane. Upon damage or stress, PINK1 moves to the outer 
membrane and phosphorylates parkin (PRKN). This phosphorylation allows for 
ubiquitination of PRKN1 and targeting to the autophagosome. Poly-ubiquitination is 
recognized by adapters that direct mitochondria to the autophagosome. Known adapters 
include sequestosome (SQSTM1), neighbor of BRCA1 (NBR1), optineurin, nuclear 
domain 10 protein 52, and TAX1 binding protein; although, NBR1 is found to be non-
essential for PRKN-mediated mitophagy [26, 32, 33]. Through this mechanism, a recent 
study found that in intestinal cancers, activation of mitophagy increased CD8+ T cells 
[34]. The upregulation of mitophagy causes an accumulation of iron followed by 
permeabilization of the lysosome. This permeabilization causes the release of proteases 
into the cytosol that induces presentation of MHC class I on the cell surface. This 
presentation elicits and an anti-tumor immune response by induction of CD8+ T-cells. In 
colitis, pharmacological induction of mitophagy through PRKN is found to inactivate 
inflammasomes in macrophages and ameliorate the impact of colitis [35-37]. While there 
are implications for PRKN mediated mitophagy in CRC, one study found around 33% of 
colon tumors harbor PARK2 (the gene that encodes for PRKN) DNA copy number loss 
[38]. Interestingly, some colorectal cancer cell lines contain mutated forms of PRKN and 
may use alternate mechanisms to activate mitophagy [38]. Research is starting to 
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investigate how PRKN may be used as a prognostic marker in CRC as it may correlate 
with invasion and overall survival [39]. 
 
Parkin-independent mitophagy 
Alternatively to PRKN directed mitophagy, interaction of LC3 to FUN14 domain 
containing 1 (FUNDC1) protein located on the outer mitochondrial membrane can also 
initiate mitophagy [40]. Another PRKN-independent mechanism includes BCL2 
interacting protein 3 (BNIP3), a critical receptor for mitophagy [41]. In breast cancer, 
BNIP3 loss promoted tumor progression and metastasis [42]. BNIP3 is induced by 
hypoxia signaling, a critical micro-environmental stressor in CRC (discussed below)[43]. 
The impact of BNIP3 and mitophagy in CRC have not been studied in detail. The known 
function in breast cancer, and BNIP3’s relationship with hypoxia signaling provides a 
foundation to investigate the role in CRC. Mitochondria may also be recruited to the 
autophagosome by FKBP8, a member of the FK506-binding protein family. FKBP8 is 
located on the outer membrane and has an anti-apoptotic role by interacting with Bcl-2 
[44]. PRKN-independent mitophagy can be initiated by binding of LC3A to FKBP8 [45]. 
Additional mechanisms of PRKN-independent mitochondrial control are reviewed by 
Stockum et al. [46]. PRKN-independent mechanisms, and the evidence of mutated PRKN 
discussed above in CRC highlight the potential importance of investigating PRKN- 
independent mitophagy in CRC.  
Pharmacological targeting of mitochondria with Mito-CP or Mito-Met10 in KRAS 
mutant colorectal cancers induced mitophagy and decreased cell proliferation [47]. In 
colon cancer, treatment with a BH3 mimetic, which inhibits Bcl-2 anti-apoptotic proteins, 
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induced mitophagy. Treatment with the mimetic, in combination with an mitophagy 
inhibitor, reduced CRC cell growth [48]. However, conflicting roles of mitophagy have 
been noted in cancer (Reviewed in [49]). Treatment with the mitophagy inhibitor liensinine 
increased breast cancer cell death [50]. Conversely, activation of mitophagy with 
ceramide, a molecule involved in sphingolipid metabolism, reduced tumor burden in acute 
myeloid leukemia [51].  In-depth understanding of mitophagy in CRC is needed in order 
to develop better therapies that can target mitophagy to reduce tumor growth.  
Ribophagy 
Ribophagy is the breakdown of ribosomes in cells, which constitute 10% of total 
cellular protein. Ribophagy is extremely low basally in cells [52]. Initiation of ribophagy 
occurs by the binding of nuclear FMR1 interacting protein 1 (NUFIP1) to ribosomes. This 
interaction leads to autophagosome recruitment by LC3 [53]. Starvation or molecular 
target of rapamycin complex 1  (mTORC1) inhibition induced NUFIP1 activity and 
increased ribophagy [53]. Breakdown of ribosomes under starvation underscores the 
importance of ribophagy for cellular nutrient maintenance. However, non-selective bulk 
degradation of ribosomes may also be utilized [52]. Little information is known about 
ribophagy in cancer. However, ribosomes contain a large amount of amino acids and 
nucleotides and can potentially serve as a nutrient store in the tumor environment.  
Proteophagy 
Clearance of proteasomes through autophagy is known as proteophagy. Cross-talk 
between the proteasome and autophagy is found under nitrogen starvation in cells 
wherein autophagy degrades ribosomes (and proteasomes) under nutrient starvation 
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[54]. One of the earliest citations of proteophagy suggests that this process occurs 
through a chaperone-mediated mechanism where the proteasome is targeted to the 
lysosome by HSC73 [55]. More recent work uncovers the sequestration of the 
proteasome in autophagosomes under cell stress, suggesting proteophagy can occur in 
a macro-autophagy or CMA driven fashion [56]. Currently there is no data to suggest that 
proteophagy is activated in cancer.  
Pexophagy 
Peroxisomes are small organelle structures that break down fatty acids in the 
cytoplasm. The degradation of these products through autophagy requires SQSTM1 and 
NBR1 [57]. In healthy liver, loss of autophagy through ATG7 led to a buildup of 
peroxisomes [58]. Under starvation conditions, ubiquitination of peroxisomes occurred by 
peroxisomal biogenesis factor 2 (PEX2) in HeLa cells and mouse embryonic fibroblasts 
[59]. To our knowledge, the utilization of pexophagy in CRC has yet to be investigated. 
However, hypoxia inducible factor-2α (HIF-2α), an important transcription factor in CRC 
(discussed below), was found to promote pexophagy in hepatocytes [60]. While these 
findings were not investigated in colon tissue, the activation of pexophagy under 
starvation and hypoxia highlights the potential importance of studying pexophagy in CRC.  
Ferritinophagy 
Iron storage protein ferritin is broken down by the lysosome for iron release and 
cellular iron utilization. This degradation is directed by the nuclear receptor coactivator 4 
(NCOA4) [61]. Interestingly, ferritinophagy is required for induction of ferroptosis, a form 
of cell death that requires iron [62, 63]. Certain cancers have shown a sensitivity to 
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ferroptosis [64] and pharmacological induction of ferroptosis is found to reduce pancreatic 
and hepatic cancer cell growth [63, 65]. While little work has been done to investigate the 
importance of ferritinophagy in CRC, the essential role of iron in CRC growth [66] and the 
sensitivity of different cancer types to ferroptosis [67] highlights the importance in studying 
ferritin turnover in CRC.   
Xenophagy 
Xenophagy is a process initiated by the cell for protection against pathogens. 
Phagophores engulf pathogens and fuse to autophagosome for breakdown by 
autophagy. Xenophagy can play a particularly important role in the colon due to the host-
microbiome interaction. Protection from intestinal epithelial infection requires the 
autophagy gene ATG16L1 [68]. Recent screening of xenophagy effectors identified a V-
ATPase and ATG16L1 mechanism to specifically activate xenophagy under bacterial 
infiltration [69]. Certain bacteria can be targeted by SQSTM1, an important protein in 
autophagy [70]. In Crohn’s Disease, the stimulation of xenophagy using resveratrol 
reduced Salmonella Typhimurium, an enteric pathogen associated with Crohn’s Disease 
[71]. When colon cancer cells are treated with two mircoRNAs, MIR106B and MIR93, 
reduced ATG16L1 prevented removal of intracellular bacteria from epithelial cells via 
autophagy [72]. As mentioned, patients with Crohn’s Disease have an increased risk of 
developing CAC and this is partially due to bacterial infiltration. Understanding the role of 
xenophagy in host-microbiome homeostasis may be essential in characterizing the 




3. Role of Autophagy in CRC  
It is important to understand the role of autophagy at different stages and under 
different mutational loads to properly target tumors. A clinical study observed down-
regulation of ATG5 in CRC patients. However, increased expression correlated with 
increased incidence of invasion [73]. Conversely, expression of LC3B and SQSTM1 
correlated with poor prognosis [74]. In mouse models, loss of Atg7 in intestinal epithelial 
cells inhibited tumor growth through an immune response elicited by the microbiome [75]. 
Additionally, receptor for activated C kinase 1 ( RACK1), a commonly found mutation in 
cancer, induced autophagy and promoted proliferation while inhibiting apoptosis in colon 
cancer [76]. Autophagy also modulated the degradation of the transcription factor 
FOXO3a in CRC. Inhibition of autophagy elevated levels of FOXO3a and led to 
transcriptional upregulation of pro-apoptotic genes [77]. Apoptosis also increased when 
autophagy was inhibited in CRC cells following activation of p53 and endoplasmic 
reticulum stress [78]. Conversely, treatment with Brevlin A increased autophagy and 
decreased tumor size [79]. This brief overview emphasizes the complexity of autophagy 
in CRC. It remains unclear if autophagy is anti- or pro- tumorigenic and in-depth 
mechanistic studies are needed. Table 1.1 outlines some of the opposing roles of 
autophagy in CRC.  
An understanding of mutations in autophagy associated genes, how autophagy is 
altered by increased mutational load, or via specific tumor suppressors or oncogenes is 
essential in assessing its role in tumor development. In CRC, there is low frequency of 
mutations in autophagy associated genes [80]. In a small cohort of patient samples, 
tumors expressed decreased levels of ATG5, however increased expression correlated 
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with invasion into lymphovascular tissue [73]. A study demonstrated that 95% of colon 
tumors expressed higher Beclin-1 compared to normal tissue [81]. These studies suggest 
that autophagy is important in cancer development. Similarly, in mutant KRAS cancers, 
autophagy induction occurred under starvation. Inhibition of KRAS reduced autophagy in 
these cells and inhibited cell growth [82]. In CRC-derived cell lines, p53 promoted the 
degradation of LC3 allowing for stable autophagic flux [83]. With loss of p53, LC3 
accumulated and led to apoptosis. In CRCs with high microsatellite instability, 27% of the 
cancers harbored at least one mutation in either ATG2B, ATG5, ATG9B, or ATG12 [84]. 
Additionally, a study aimed to understand responsiveness to therapy in BRAF (a protein 
involved in RAS/MAPK signaling) mutant colon cancers found that treatment with EGFR 
antibodies and checkpoint inhibitors induced autophagy and combining these treatments 
with an autophagy inhibitor reduced CRC cell growth [85].  Patients with Crohn’s Disease 
have an increased chance of developing CAC. Deficiencies in the response to bacterial 
sensing and invasion were observed following loss of autophagy through impairment in 
nucleotide-binding oligomerization domain (NOD1/2) signaling [86]. Loss of autophagy or 
mutations in autophagic genes may increase bacterial infiltration, which can impact the 
development of CAC. Mutations in autophagy associated genes, or regulation of 
autophagy through mutations in genes such as KRAS and p53, demonstrate the 
important role of this mechanism in CRC. To begin addressing how autophagy can be 
used clinically, researchers have found a gene signature based on nine autophagy related 
genes that can accurately predict survival in colon cancer [87].  
Histone deacetylase inhibitors as stand-alone or adjuvant therapies are currently 
used in several cancers [88]. In colorectal cancer cells, inhibition of autophagy through 
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chloroquine, in combination with the histone deacetylase inhibitor vorinostat, led to an 
accumulation of ubiquitinated proteins and increased cell death [89]. Additionally, chemo-
resistance required decreased autophagy in 5-fluorouracil (a common chemotherapeutic 
for CRC) resistant cells [90]. The authors speculated, that this observation was due to 
low autophagy resulting in accumulation of tumor promoting oxidative stress, 
inflammation, and damaged mitochondria. 
CRC consist of multiple epithelial cell types as well as infiltrating immune cells. In IBD 
it is clear that dysregulation of autophagy in Paneth cells impacts tissue injury and 
inflammation [91]. However, cell type specificity of autophagy in tumor growth is unclear.  
Immune cell autophagy: The anti-tumor immune response can directly kill cancer 
cells. As the tumor progresses, the microenvironment shifts to a highly 
immunosuppressive state and many of the immune cells potentiate tumor growth. 
Immunosuppression is essential in enhancing tumor progression, and immune cells can 
employ autophagy to perform standard functions including antigen presentation and 
cytokine production (Reviewed in [92]). In tumor-associated macrophages (TAM)s, 
upregulation of autophagy reduced tumor growth and increased apoptosis in CRC cells. 
Moreover, radiosensitization of CRC required increased autophagy in TAMs [93]. 
Conversely, when autophagy is lost in regulatory T-cells by disrupting Atg7, there was 
impaired ability of the antitumor immune response to CRC cells [94]. This was due in part 
by increased apoptosis in the T-cells. While not specifically studied in colon cancer, 
different immune cells including neutrophils, macrophages, B-cells, and natural killer cells 
rely on autophagy for their development and function (Reviewed in [95]). Immune cell 
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specific autophagy underscore the importance of investigating this pathway in different 
cell types to better develop strategies for modulating tumor growth.  
Epithelial autophagy: Tumor epithelial autophagy in KRAS driven cancers alters 
inflammatory mediators to suppress the immune response [96]. Furthermore, inhibition of 
autophagy in cancer cells blocked interferon gamma-mediated cell death [97]. The role 
of the immune system and its interaction with the gut microbiota is important in tumor 
development. Cell autonomous autophagy in healthy epithelial cells altered barrier 
function by breaking down junctional proteins such as claudin 2 [98]. Impaired barrier 
function can lead to increased bacterial infiltration to cause inflammation and damage in 
the gut. Recent work demonstrated tumor stage specific changes in bacterial infiltration, 
inflammatory signaling and cancer progression and growth in CRC [99]. This suggests a 
possible role of epithelial xenophagy in CRC. In CRC tumors, regulatory T-cell infiltration 
inversely correlated with SQSTM1 expression [100]. The utilization of autophagy in 
epithelial cells may alter recruitment or function of the immune response. In summary 
there are major differences in the direct impact of autophagy in epithelial cells, immune 
cells, or the heterocellular cross-talk between these cells that can impact CRC growth 
and progression (Figure 1.2). Understanding the changes in autophagy and how it 
impacts tumor response will allow researchers to further understand these mechanisms 
in different cell types.  
4. Cellular cues for autophagic activation in cancer   
Starvation  
The highly proliferative nature of tumors leads to a reduction in availability of nutrients 
in the microenvironment. In cancer, hyper-activation of mTORC1, a known pathway of 
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nutrient sensing, contributes to cell proliferation and tumor progression. mTORC1 is 
activated in about 50% of CRC tumors. Figure 1.3A outlines the known mechanistic 
cross-talk in CRC between autophagy and mTORC1. In conditions where amino acids 
are abundant, mTORC1 is localized to the lysosomal membrane (Reviewed in [101]). 
Hypoxic induction of DNA damage inducible transcript 4 (REDD1) signaling has been 
shown to regulate mTORC1 through truncation of the hemartin (Tsc1/Tsc2) complex 
[102]. Since mTORC1 is activated by available nutrients, a feedback loop exists between 
these two mechanisms wherein autophagy generates new macromolecules to activate 
mTORC1. The cross-talk between these two mechanisms are essential in maintaining 
cell growth and proliferation [102]. Importantly, mTORC1 is integrated to the autophagic 
pathway via activation of TFEB and ULK1-ATG13-FIP200 (Family kinase-interacting 
protein of 200kDa) complex [103, 104]. Independent of mTORC1, AMPK activated the 
ULK1 complex under starvation [105]. Under nutrient rich conditions mTORC1 
phosphorylated ULK1 and inhibited the ULK1-AMPK interaction to block autophagy [105]. 
It is important to consider that the TFEB, ULK1, and AMPK pathways are known to be 
regulated by amino acids, which contributes to another mode of autophagy regulation 
[106]. In a model of lung cancer, amino acid starvation led to an induction of non-selective 
macro-autophagy. However, amino acid starvation has been shown independent of 
mTORC1 to induce micro-autophagy that directly engulfs receptors of selective 
autophagy including NCOA4, LC3B, and SQSTM1 into endosomes [20]. The authors 
suggest these functions may prevent selective macro-autophagy and promote non-
selective autophagy under starvation. Interestingly, under leucine starvation, a cleaved 
form of SQSTM1 is generated by the protease caspase-8. Under starvation when 
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autophagy is active, a portion of the available SQSTM1 is cleaved. In nutrient replete 
conditions, this cleaved protein activates mTORC1 to increase leucine sensing [107]. The 
cleaved SQSTM1 is not able to participate in autophagy preventing opposing functions 
between mTORC1 and autophagy. Moreover, in ovarian cancer cells, arginine deprivation 
activated autophagy to promote cell survival [108]. Inhibition of autophagy both chemically 
or genetically significantly reduced cell growth. While these studies were not in CRC, 
these findings highlight the potential of combinatorial therapeutics with autophagy 
inhibitors and treatments such as arginase for tumors that rely on arginine for growth 
[108]. Glucose uptake plays a critical role in the growth of many cancer types, including 
CRC. In glucose-free conditions, knock-down of autophagy associated genes increased 
cell death [109]. Similarly, when colon cancer spheroids were stressed under restricted 
glucose or serum an increase in autophagy was observed [110]. Under similar starvation 
conditions, Kras mutant tumors require autophagy for oxidative metabolism [111].  
Starvation also affected expression of claudin 1 in colon cancer. Expression of claudin 1 
was higher in tumor tissue and showed co-staining with lysosomal markers LAMP1 and 
2 with increased autophagy. Under starvation, claudin 1 expression increased mediating 
a reduction in SQSTM1. This supression suggests claudin 1 cross-talks with autophagy 
under starvation [112]. When and how nutrient availability impacts autophagy is essential 
in understanding its function in CRC tumors (Figure 1.3B).  
Hypoxia  
Hypoxia plays a key role in CRC development and progression. Hypoxia 
signaling is mediated by two conserved transcription factors hypoxia-inducible factor 
(HIF)-1 and HIF-2, which have overlapping and distinct functions. In CRC, HIF-2 
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(not HIF-1) is essential for CRC growth and progression [113]. Hypoxia is a well 
conserved cell stress that activates autophagy [43]. In tumor hypoxic foci, autophagy 
levels are highly elevated but rapidly subside upon establishment of a blood supply 
[114]. In colon cancer there is a known connection between hypoxia and mitophagy. 
Hypoxia disrupted mitochondrial respiration leading to increased mitophagy (Figure 1.2) 
[115]. Moreover, HIF-1α upregulated BNIP3 to induce mitophagy [43]. In patient derived 
CRC cells, inhibition of autophagy with 3-Methyladenin in combination with hypoxia, 
increased apoptotic death in cancer cells [116]. Moreover, the micro RNA miR-20a was 
found to inhibit hypoxia induced autophagy [117]. Additionally, in glioblastoma, HIF-1 
induced autophagy and drove tumor growth [118]. HIF-1 does not alter CRC 
tumorigenesis in mouse models [113], however it will be interesting to assess if HIF-2 
has overlapping roles in the context of autophagy. 
Microbiota  
As highlighted briefly above, autophagy can play an important role through 
xenophagy in managing the host-microbiome interaction. Moreover, dysregulation of 
autophagy is well characterized in IBD. New work studying chronic colitis suggests that 
autophagy protected cells by reducing apoptosis through upregulation of tumor necrosis 
factor- [119]. As discussed above, the importance of autophagy specifically in Paneth 
cells is known [91]. In healthy tissue, induction of autophagy in Paneth cells induced 
interferon gamma to protect against microbiota. However, when this mechanism is lost, 
intestinal inflammation is exacerbated [120]. Consistent with data from IBD, the 
heterocellular cross-talk with microbiota is a major factor in tumor-elicited inflammation in 
CRC. When microbiome composition is altered under chronic inflammation or barrier 
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defects, changes in the inflammatory response altered tumorigenesis [121, 122]. The 
cross-talk between the microbiota and immune system highlights the complexity of the 
tumor microenvironment in the colon [123, 124]. The importance of these mechanisms 
have been studied in depth [125, 126]. Loss of autophagy in healthy colon epithelial cells 
through Atg5 disruption altered the composition of the gut microbiota and the gut immune 
response suggesting implications in chronic colitis [127]. Similarly, loss of Atg7 in 
intestinal epithelial cells and tumor tissue led to infiltration of anti-tumor immune cells 
decreasing tumor burden [75]. Treatment with antibiotics attenuated this response, further 
supporting a novel integration of microbiota and autophagy in tumor growth. It is important 
to highlight that this work utilized an Apc model where tumor suppressor p53 was intact. 
In many cancers however, p53 is deleted or mutated thus these findings may only be 
applicable to patients with wild-type p53 [75]. In summary, the above findings highlight 
the cross-talk between the microbiota and autophagy. Further mechanistic studies may 
uncover novel therapeutic approaches targeting autophagy and microbiota.  
5. Autophagic Substrates 
The broad use of autophagy to meet metabolic demands is reviewed by Rabinowitz 
and White [128]. Autophagy in normal cell physiology is critical to maintain amino acid 
levels [129]. While it is thought the products of autophagic degradation are recycled for 
use in cancer, in CRC the substrates targeted for autophagy and how the degradative 
products are utilized is not clear. In cancer, autophagy can degrade macromolecules for 
nutrients, and degrade tumor suppressors or oncogenes to alter growth. Below we outline 




Previous literature has found an increase in autophagy in CRC spheroids under 
glucose or serum restriction [110]. However, the degradative products of this process are 
unknown. A study investigated this question by studying loss of ATG5 in RAS driven 
cancer cells. Loss of ATG5 showed global changes in the proteome. Inhibition of 
autophagy, in combination with starvation, increased endoplasmic reticulum chaperones, 
proteins involved in DNA replication, and Rig-I like receptor signaling pathway. However, 
proteins that are known to be essential in stress survival were not altered with autophagy 
inhibition under starvation conditions [96]. This work uncovers how autophagy impacts 
cellular response to stresses such as starvation that are observed in the tumor 
microenvironment. Additionally, in RAS driven cancers, autophagy drove glycolysis [130]. 
Degradation of cellular components into amino acids is essential for cancer utilization. 
Thomas and colleagues demonstrated that amino acid levels in starved breast cancer 
cells increased with activated autophagy, whereas normal cells maintained amino acid 
levels under starvation. It is hypothesized that this is due to the high nutrient demand to 
maintain the proliferation rates of the cancer cells [131]. While this study was not in CRC 
this underscores the importance of understanding how autophagy is used for nutrient 
acquisition.  
While autophagy may be employed to acquire nutrients, it has been shown to break 
down proteins that activate or block tumor growth.  Autophagy can cause the degradation 
of dishevelled in colon cancer and contribute to the activation of Wnt signaling, thus 
promoting tumor growth [132]. Similarly in CRC, the cancerous inhibitor of protein 
phosphatase 2a (CIP2A) is overexpressed [133]. CIP2a is involved in Myc protein 
stability. Temsirolimus, an FDA approved mTORC1 inhibitor that activates autophagy led 
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to degradation of CIP2a and cell death in CRC [134]. In colon cancer, CyclinD1 is highly 
expressed and contributes to hyper-proliferation. Estrogen receptor beta was shown to 
activate autophagy and cause the breakdown of CyclinD1 causing cell cycle arrest and 
tumor death [135]. To prevent growth, treatment with 4-hydroxytamoxifen caused 
degradation of KRAS through autophagy in colon cancer [136]. As mentioned previously, 
basal autophagy breaks down FOXO3a to prevent apoptosis in CRC, to promote tumor 
growth [77]. While some work has been done, the process of breaking down proteins to 
inhibit or promote tumor growth are not well studied. A thorough understanding of 
autophagy in the context of CRC is important in targeting these mechanisms. 
 
6. Conclusions and Future Perspectives  
In general, non-selective autophagy is used for nutrient stress while selective 
autophagy is used for cell maintenance. However, in the context of tumor growth in CRC 
or CAC, these roles may change. Understanding the autophagic substrates that are 
recycled and how those substrates are utilized in tumor growth and development will 
identify ideal targets for treatments. While we have discussed mechanisms by which 
tumor cells may obtain nutrients through autophagy, these mechanisms are not clearly 
defined in CRC. The cross-talk between hypoxia and mitophagy underscores the 
importance of these mechanisms in CRC. Identifying the role of selective autophagy for 
tumor growth will allow the development of targeted therapeutics for CRC. The potential 
importance of mitophagy in cell stress and nutrient availability highlights a potential target 
in cancers. Moreover, if tumor cells employ selective autophagy for growth and survival, 
these mechanisms may be targets for vulnerability in CRC. Some of these approaches 
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are reviewed by Martins and Baptista [137]. Additionally, we have highlighted the cell type 
specific contributions of autophagy and more precise work on cell type specific 
dependency on autophagy will shed light on the mechanistic role of autophagy in tumor 
development. More directly, the pathways activated or inhibited during nutrient stress and 
how autophagic substrates are being utilized in cancer cells will be critical to 
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Figure 1.1. Overview of autophagy subtypes; macro-autophagy, micro-autophagy, 












Table 1.1A. Autophagy performs tumor promoting and tumor suppressive roles 
in CRC. Functions of autophagy in CRC. A. Observation/Autophagy indicates what 
mechanisms are observed in CRC tumors and if autophagy is active or inactive. Tumor 
response is a summary of whether or not the autophagy activity indicated generates a 
pro- or anti- tumor response. B. Summary of therapies and their modulation of autophagy. 
Treatment- Which therapy was employed. Autophagy- how the stated therapy modulated 
autophagy activation. Tumor response- how manipulation of autophagy via therapeutic 
treatment impacted tumor growth.  
Observation Autophagy  Tumor response  Reference  
Activated chaperone 
mediated autophagy 
in tumors  




Active  Anti-tumor  34 
Loss of PARK2 
accelerates tumor 
development  
Inactive  Pro-tumor  38 
Decreased ATG5 in 
CRC patients  




Active  Pro-tumor  73 
Active autophagy 
through LC3B and 
SQSTM1 
Active  Pro-tumor  74 
Loss of ATG7 Inactive  Anti-tumor  75 
RACK1 induces 
autophagy 
Active  Pro-tumor  76 
High Beclin-1 in CRC  Active  Pro-tumor  81 
Increased LC3 with 
loss of p53 
Active  Anti-tumor  83 
Autophagy 
suppresses immune 
response in KRAS 
cancer  
Active  Pro-tumor  96 
Autophagy drives 
glycolysis in RAS 
cancers  















proliferation in KRAS mutant 
cancers.  
47 
BH3 mimetic and 
chloroquine 
Inactive  Anti-Tumor; Induced apoptosis. 48 
Bafilomycin A1 or 
chloroquine 
Inactive  
Anti-Tumor; Elevated FOXO3a 
and transcriptional upregulation 
of pro-apoptotic genes.  
77 
 Brevlin A  Active  
Anti-Tumor; Promoted 
expression of LC3-II and 
induced autophagy. 
79 
KRAS siRNA Inactive  
Anti-Tumor; Inhibiting mutant 





Inactive  Anti-Tumor; Induced apoptosis. 89 
 5-Fluorouracil and 
chloroquine 
Inactive  
Anti-Tumor; 5-FU treatment 
induced autophagy for 
resistance. Inhibition of 
autophagy reduced growth. 
90 
Temsirolimus  Active  
Anti-Tumor; Inhibited mTOR to 







directed CyclinD1 degradation 
inhibited growth. 
135 
4-Hydroxytamoxifen   Active  
Anti-Tumor; Degradation of 
KRAS through autophagy 









Figure 1.2. Cell-autonomous and non-autonomous cures of autophagy in 
CRC. Schematic of the tumor microenvironment highlighting the impact of 
autophagy. Cell autonomous roles of autophagy in immune, epithelial or, the 















Figure 1.3. Mechanisms of mTOR and nutrient modulation impacted by 
autophagy. Schematic summarizing A) Simplified overview of mechanisms of 
mTORC1 regulation. and B) how nutrient modulation impacts autophagy. Bolded 
mechanisms indicate data from non-CRC samples. Please refer to text for 








Colorectal Cancer Cells Rely on Mitophagy for Tumor Growth. 
Abstract  
 
Cancer cells re-program cellular metabolism to maintain adequate nutrient pools 
to sustain proliferation.  Moreover, autophagy is a regulated mechanism to breakdown 
dysfunctional cellular components and recycle cellular nutrients.  However, the 
requirement for autophagy and the integration in cancer cell metabolism is not clear in 
colon cancer.  Here we show a cell-autonomous dependency of autophagy for cell 
growth in colorectal cancer. Loss of epithelial autophagy inhibits tumor growth in both 
sporadic and colitis associated cancer models. Genetic and pharmacological inhibition 
of autophagy inhibits cell growth in colon cancer-derived cell lines and patient-derived 
enteroid models. Importantly, normal colon epithelium and patient-derived normal 
enteroid growth was not decreased following autophagy inhibition.  To couple the role of 
autophagy to cellular metabolism, a cell culture screen in conjunction with metabolomic 
analysis was performed.  We identified a critical role of autophagy to maintain 
mitochondrial metabolites for growth. Under stress, cancer cells activate mitophagy to 
                                                          
2 This chapter represents a submitted manuscript: Devenport SN, Singhal R, Taranto JG, Kerk 
S, Oravecz-Wilson K, Greenson JK, Soleimanpour SA, Reddy P, Lyssiotis CA, Shah YM. 
Colorectal cancer cells employ mitophagy for nutrient acquisition under cell stress. Under 




access nutrients for growth. Loss of mitochondrial recycling through inhibition of 
mitophagy hinders colon cancer cell growth. These findings have revealed a novel cell-
autonomous role of autophagy that plays a critical role in regulating nutrient pools in 

























Autophagy is an important process involved in maintaining cellular homeostasis. 
Autophagy removes defective organelles and proteins through lysosomal break down. 
This process can occur via macro-autophagy (herein autophagy); the non-selective 
engulfment of cytoplasmic contents, or through selective autophagy which targets 
specific cargo. In colon cancer, autophagy is found to have both pro- and anti- tumor 
functions in cancer-derived cell lines [1-3]. Consistent with this data, studies have also 
found both beneficial and deleterious roles of autophagy in clinical outcomes in 
colorectal cancer (CRC) patients [4-6]. Therefore, the function of autophagy in 
colorectal cancer (CRC) currently remains unclear. In mouse models of colon cancer, 
intestinal epithelial disruption of Atg7, a gene involved in formation of the 
autophagosome membrane, led to decreased tumors [7]. The work demonstrated that 
intestinal epithelial inhibition of autophagy promoted an anti-tumor immune response via 
alterations in the commensal microbiota population. This data is consistent with 
changes in the basal gut microbiota following intestinal epithelial Atg5 disruption [8].  
The tumor microenvironment increases cell stress caused by decreased oxygen 
availability, reduced nutrient supply, and anti-tumor immune response. To adapt to 
limited oxygen and nutrients, cancer cells modify metabolic pathways to maintain 
growth. One mechanism is through utilizing autophagic products to replenish nutrient 
pools in cancer [9-15]. However, all of this work has been done in KRAS mutant tumors 
and very little is known with respects to contribution and integration of cellular 
autophagy to colon cancer cell metabolism and growth.   
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In the current study, we identified a cell-autonomous dependency of autophagy in 
colon cancer cell lines, patient-derived enteroids, and mouse models. Loss of epithelial 
autophagy in murine tumor models reduced overall tumor number, tumor burden, and 
proliferation. Consistent with these data, tumor growth and proliferation were 
significantly decreased in CRC-patient derived enteroid models, but not in normal 
enteroids.  In nutrient starved environments, colon cancer cells require autophagy to 
maintain cellular nutrient pools. Through metabolomics and lysosomal proteomics, 
mitophagy was rapidly initiated in low nutrient conditions and recycling of mitochondrial 
metabolites was observed.  Temporal knockdown of mitophagy led to decreased colon 
cancer cell growth in nutrient rich cell culture conditions. These data demonstrate that 
CRCs are addicted to mitophagy to maintain cell growth. There are several clinical trials 
targeting autophagy for cancer treatment, and this work establishes a critical role of 














Intestinal epithelial disruption of autophagy inhibits colon tumor growth. 
Atg5fl/fl mice were crossed to mice expressing Cre recombinase from the Villin 
promoter to specifically target intestinal epithelial cells. The azoxymethane (AOM) and 
dextran sulfate sodium (DSS) model is an established colitis associated cancer (CAC) 
model that specifically develops colon tumors. In the AOM/DSS model, Atg5fl/fl  and 
VillinCre;Atg5fl/fl mice showed no significant difference in body weight, although a slight 
decrease was noted in the VillinCre;Atg5fl/fl mice during the final cycle of DSS (Figure 
2.1A). The VillinCre;Atg5fl/fl mice demonstrated a decrease in tumor number, size, and 
burden (Figure 2.1B). Tumors from VillinCre;Atg5fl/fl mice had reduced proliferation as 
measured by Ki67 staining (Figure 2.1C&D). However, we did observe in the few rare  
large tumors from the VillinCre;Atg5fl/fl, that proliferation was comparable to Atg5fl/fl mice 
(Figure 2.1C&D). Previous work investigating loss of Atg7 in intestinal epithelial cells 
highlighted the impact of the immune response and gut microbiota in tumors [7]. 
Cytokines and chemokines mRNA were measured and no change was found between 
the Atg5fl/fl or VillinCre;Atg5fl/fl mice (Figure 2.1E). Similarly, loss of intestinal epithelial 
autophagy did not alter disease susceptibility to acute colitis induced by DSS. No 
changes in weight, colon length, or inflammation score as determined by a blinded 
pathologist were noted (Figure S2.1 A-D&F). Expression of cytokines and chemokines 
was not altered with loss of autophagy (Figure S2.1E). Transcription factor EB (TFEB) 
activates genes involved in autophagosome formation, cargo recognition, and fusion 
with the lysosome. When autophagy was disrupted by loss of TFEB in a tamoxifen 
inducible Vil-ERT2;Tfebfl/fl model, there was no change in weight, colon length, or 
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inflammation score (Figure S2.1 G-J&L). However, select inflammatory mediators 
including Tnfα, Cxcl1, Cxcl2, Il10, and Cdllb were significantly increased (Figure 
S2.1K). While we did not observe effects of autophagy loss on the response to acute 
colitis, others have clearly demonstrated a role for intestinal epithelial autophagy in 
colitis severity [17-19]. Genome wide association studies have linked polymorphisms of 
many known autophagic genes to susceptibility for ulcerative colitis or Crohn’s Disease 
[20, 21]. Moreover, the data from the Vil-ERT2Cre;Tfebfl/fl  model showed increased pro-
inflammatory mediators following injury. Therefore, the development of tumors through 
AOM/DSS is confounded by an inflammation driven tumor development. A sporadic 
colon tumor model was generated by crossing the Apcfl/fl or the double Apcfl/fl;Atg5fl/fl 
mice to a tamoxifen-inducible colon specific Cdx2-ERT2Cre [22].  Mice were induced 
with a single dose (50mg/kg) of tamoxifen and 6-weeks following injections, tissues 
were collected. Mice showed no difference in body weight (Figure 2.2A). The Cdx2-
ERT2Cre;Apcfl/fl;Atg5fl/fl  showed a significant reduction in tumor number and burden 
compared to Cdx2-ERT2Cre;Apcfl/fl mice (Figure 2.2B). Proliferation measured by Ki67 
was reduced with loss of Atg5 (Figure 2.2C). Adjacent normal tissue showed no 
difference in proliferation with autophagy loss (Figure 2.2D). To investigate if infiltration 
of immune cells was altered in the sporadic model following loss of autophagy, flow 
cytometry analysis of abundant immune populations were assessed. Two weeks 
following tamoxifen induction, immune cells were isolated from the colon. No difference 
was observed between the relative monocyte, T-cell, or neutrophil populations (Figure 
2.2E). In inflammatory bowel disease (IBD), Paneth cells are particularly impacted by 
changes in autophagy [23, 24]. Therefore, we performed gene expression analysis of 
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Paneth cell markers in our Cdx2-ERT2Cre;Apcfl/fl;Atg5fl/fl  cohort and found no changes in 
Paneth cells with loss of autophagy in either tumor or matched normal tissue (Figure 
S2.1M).  
Autophagy loss inhibits tumor proliferation in a cell-autonomous manner. 
CRISPR/CAS9 mediated disruption of TFEB in CRC-derived HCT116 cells 
(Figure 2.3A) showed a marked reduction in growth as assessed by MTT and long-term 
clonogenic cell survival assays (Figure 2.3B-D). In addition, doxycycline inducible 
shRNAs for TFEB in HCT116 and SW480 cell lines demonstrated reduced growth 
(Figure 2.3E-K). Empty vector controls are not impacted by treatment with doxycycline 
(Figure S2.2A). ATG4B is an essential regulator of autophagy [25]. Stable HCT116 
cells expressing a dominant negative ATG4BC74A mutant demonstrated decreased 
growth by MTT and clonogenic analysis (Figure S2.2 B&C) [26]. Pharmacological 
inhibition of autophagy is currently in clinical trials for a number of cancers 
(NCT02333890; NCT02378532; NCT03400865). To understand the impact of 
pharmacological inhibition, growth in CRC-derived cell lines was measured following 
treatment with chloroquine, a lysosomal inhibitor. In CRC-derived cell lines (SW480, 
HCT116, DLD1), increasing doses of chloroquine led to marked reduction in cell growth 
(Figure 2.4A). Similar response was observed in CRC-derived HT29, RKO, and mouse 
MC38, and CT26 cell lines (Figure S2.3A). Autophagy can be activated by serine, 
threonine protein kinase 1 (ULK1) [27]. Inhibition of ULK1 with SBI-0206965 also 
reduced cell growth similar to chloroquine (Figure S2.3B). Cell growth was rescued 
when low dose (but not high dose) chloroquine was removed (Figure S2.3C).  
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To assess if the impact of autophagy loss to cell growth was selective to tumor 
cells, four patient-derived tumor enteroids and two normal colon enteroids were 
assessed [28]. Enteroids 282,584, and 590 are adenomas located in the ascending 
colon and enteroid 245 is an adenoma: sessile serrated from the cecum. Patient-
derived tumor enteroids demonstrated significant growth inhibition following chloroquine 
treatment, where normal colon enteroids did not demonstrate any growth defects 
following inhibition of autophagy (Figure 2.4B-C and S2.3D). It is interesting to note 
that a sessile serrated tumor enteroid did not respond to autophagy inhibition. Sessile 
serrated tumors are a recently recognized class of colon cancers that present with 
BRAF mutations compared to APC mutations that are seen in the majority of colon 
cancer [29, 30]. The inhibition of growth highlights a dependency on autophagy in tumor 
cells that is not observed in normal tissue.  
 
Tumor cells rely on autophagy under states of limited nutrient availability. 
To understand if the dependency of autophagy in tumor cells is linked to cellular 
metabolic demands, we established a low dose of chloroquine or low nutrient conditions 
that did not alter cell growth (Figure 2.5A&B and S2.4A). Cells cultured in a low 
nutrient condition in combination with low dose chloroquine significantly decreased cell 
growth (Figure 2.5C) compared to either treatment alone. To understand the cellular 
metabolic demand that require autophagy, we heat inactivated serum at 95 C (herein 
SerumHI) compared to the standard 52 C to remove heat labile nutrients. Similar to 
reduced serum, SerumHI combined with autophagy loss reduced cell growth (Figure 
2.5D). Glucose or iron depletion did not have an additive or synergistic effect on cell 
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growth in combination with autophagy inhibition (Figure S2.4B&C). Moreover, 
supplementing insulin and epidermal growth factor (EGF) did not rescue the growth 
defect (Figure 2.5E&F). The additive effect of autophagy loss with SerumHI was similar 
following ULK1 inhibition (Figure S2.5A). To identify which metabolites were impacted 
under autophagy loss in combination with nutrient stress, the intracellular metabolomes 
of SW480 cells treated with SerumHI or chloroquine at 2.5µg/mL or co-treated with 
SerumHI or chloroquine for 2-days were analyzed via liquid chromatography/mass 
spectrometry (LC/MS) (Figure 2.5G). This time point was selected as no change in 
growth is observed at 2-days (Figure 2.5D). Interestingly, we found only slight changes 
in the metabolome with either treatment alone, consistent with our growth data 
However, co-treatment led to significant changes in several metabolites. Metabolites 
which were significantly changed in the SerumHI and chloroquine group were analyzed 
for pathway analysis using Metaboanalyst [31]. A significant mitochondrial metabolite 
signature was found (Figure 2.5G-H). However, supplementation of individual 
metabolites did not rescue the growth defects (Figure S2.6A). This suggests that a 
combination of metabolites is important in altering cell growth.  
 
Colorectal cancer cells use mitophagy to meet cellular metabolic demands.  
Alterations in metabolites involved with the TCA cycle suggested an impact on 
mitochondria. Mitochondria can be targeted by autophagy through a process of 
selective autophagy known as mitophagy [32]. To assess if mitophagy is essential in 
CRC to meet the metabolic demands for proliferation, mitophagy flux was assessed in 
CRC-derived cell lines. The mitochondrial specific protein cyctochrome c oxidase 
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subunit 8 (COX8) fused to two fluorescent reporters, mCherry and green fluorescent 
protein (GFP) (COX8-mcherry-GFP) was used. If mitochondrial are targeted to the 
lysosomes GFP fluorescence is quenched upon a change in pH, where mCherry 
fluorescence remains (Figure 2.6A) [33]. Using flow cytometry in HCT116 and SW480 
expressing Cox8-mCherry-GFP and cultured in SerumHI conditions demonstrated an 
increased flux in mitophagy following nutrient stress (Figure 2.6B). To further validate 
this observation, proteomic analysis was performed in lysosomes in control or SerumHI 
conditions. A stable TMEM192 expressing HCT116 cell line was established to enrich 
for lysosomes via immunoprecipitation using a LysoIP method (Figure 2.6C&D) [34]. 
Lysosomal proteomics demonstrated an enrichment of mitochondrial proteins in the 
cells under SerumHI (Figure 2.6E). The total lysosomal proteome content consisted of 
~8% mitochondrial proteins, in which 90% of all mitochondrial proteins identified where 
higher in the lysosomes of SerumHI treated cells. This data demonstrates that mitophagy 
is integrated with the cellular nutrients needs and is upregulated during nutrient stress.  
 
Mitophagy is essential for CRC growth.  
To understand the contribution of mitochondrial targeting to the lysosome for 
CRC growth mitophagy was genetically inhibited. PTEN-induced kinase 1 (PINK1) is 
important for inducing mitophagy [35]. PINK1 is involved in PINK1/Parkin (PRKN) 
mediated mitophagy and phosphorylates PRKN which is then polyubiquitinated and 
targeted for autophagic degradation. We generated doxycycline inducible shRNA 
constructs targeting PINK1 in SW480, HCT116, and RKO cells (Figure 2.7A-C). 
Knockdown of PINK1 in these cell lines significantly reduced growth when assessed by 
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MTT assay (Figure 2.7A-C and S2.7E). Similarly, knockdown of PRKN in HCT116 and 






Autophagy is a cellular process that allows for the sequestration and breakdown 
of organelles and cellular components. Autophagy is found to be both pro-and anti-
tumorigenic [36-38]. Heterocellular crosstalk exists between tumor epithelium and the 
microenvironment, and current work in CRC mouse models demonstrates an important 
role of epithelial autophagy in sustaining an immunosuppressive environment via gut 
commensals [7]. Importantly, the activation of autophagy in colon cancer is found to be 
context dependent on microbial infiltration, inflammation, and tumor stage [7, 39-42]. 
While autophagy is often thought to be a mechanism for nutrient recycling, or 
degradation of dysfunctional organelles, the precise role in colon cancer is not known. 
Specifically, the metabolic cues which activate autophagy, and the cellular metabolites 
which autophagy provide to maintain growth have not been investigated in colon 
cancer. We have shown that loss of autophagy through ATG5 inhibits tumor growth in a 
cell-autonomous fashion in inflammation-driven (AOM/DSS), sporadic (Apc), and patient 
derived in vitro models of CRC. Mechanistically we show that under nutrient stress 
autophagy is directly integrated to meet nutrient demands via mitophagy.  
In two CRC tumor models, we observed no changes in immune cell infiltration or 
immune signaling as previously described [7]. The lack of immune response in our 
models could potentially be due to the differences in the functions of ATG5 and ATG7. 
Autophagy associated genes, including ATG7 are found to have autophagy 
independent functions [43]. Other differences may be attributed to experimental design. 
For our experiments we use littermate controls and standardized the microbiome by 
mixing the bedding prior to tumor induction to prevent potential microbiota differences 
[44]. It is also documented that microbiota differ based on housing facilities [45]. While 
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other studies have identified immune differences, our experimental design and potential 
microbial differences allowed us to highlight the cell-autonomous role of autophagy in 
tumor development.  
The hyper-proliferative nature of tumor cells reprograms cellular metabolism and 
activate pathways to replenish nutrient pools in tumor cells. In pancreatic cancer, cells 
scavenge for extracellular proteins to acquire amino acids [46]. Breast cancer utilizes 
autophagy under starvation to maintain amino acid levels [47]. In our study, we have 
identified autophagy as a key function that colorectal cancer cells rely on for 
proliferation. Our in vitro cell models are cultured in a highly nutrient rich medium. Upon 
a challenge with pharmacological or genetic autophagy inhibition, growth is dramatically 
reduced. This suggests that colon cancer cells are addicted to autophagy for growth 
and have adapted to rely on this mechanism for proliferation. To integrate autophagy to 
cellular metabolic demands, we found that loss of heat labile nutrients in serum, (but not 
iron or glucose), led to a robust decrease in cell growth in combination with autophagy 
inhibition. However, these results suggest that nutrients acquired through autophagy, 
and more specifically, mitophagy are required for general cell maintenance in tumors. 
This is supported by the basal levels of mitophagy that we observed in CRC cells under 
nutrient rich culture conditions. While we were unable to rescue growth with individual 
supplementation of nutrients, it is possible that the combination of nutrients acquired 
through mitophagy are required for cell proliferation. The metabolomics data, the rapid 
decrease in cell growth when autophagy and mitophagy are inhibited, and a potentiation 
of reduced cell growth in combination with nutrient stress suggest that a major role of 
mitophagy is to replenish the nutrient pool in cancer cells. However, a decrease in 
47 
 
growth could also be due to reduced recycling of defective mitochondria. Moreover, 
autophagy is essential in regulation of proteins critical for cell growth [48]. Future work is 
focused on decoupling the importance of nutrient recycling to other autophagic functions 
in colon cancer cell growth.  
To clearly understand the role of autophagy in CRC, patient-derived enteroid 
models and adjacent normal enteroids were utilized. Patient-derived tumor enteroids 
[28] treated with chloroquine showed a marked decrease in growth when compared to 
patient derived normal enteroids. The tumor selective response further highlights the 
essential role of autophagy modulation in tumor growth. Interestingly, we observed no 
growth inhibition in the BRAF mutant (Val600Glu) enteroid model. BRAF mutations are 
present in about 10% of patients [49]. This particular enteroid was generated from a 
sessile serrated tumor [28] and BRAF mutations are known to be drivers for this tumor 
type [29, 30]. We are not aware of any literature that investigates the functional role of 
autophagy in sessile tumors but this finding uncovers the importance of understanding 
autophagy under different mutational burdens. Furthermore, it is important to consider 
the mutational load present within the models used in our study and others. p53 is 
mutated in about 50% of colon cancers [49].  However, the ATG7 model discussed 
above [7], and our AOM/DSS and sporadic tumor models, typically do not harbor p53 
mutations [50, 51].  Extensive work is needed to understand the genotypic variability in 
CRC to autophagy inhibition.  
We have identified mitophagy as an important selective pathway for nutrient 
acquisition in colon tumors. Mitophagy is a newly studied modulator of cancer growth 
and its particular role in colon cancer is not well understood. A study identified DNA 
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copy number loss of PRKN (PARK2 gene) in about 33% of the colon tumors screened. 
PRKN deletion enhanced tumor growth in Apc+/Min mice.  In addition to PRKN being 
important in mitophagy, PRKN is an E3 ubiquitin ligase for cyclin E.  Loss of PRKN led 
to an increase in cyclin E and progression of the cell cycle [52]. Moreover, mitophagy in 
tumor epithelium was shown to activate CD8+T-cells to reduce tumor burden in the 
colon [53].  The cell-autonomous role of mitophagy was not directly assessed on cell 
growth. Here, our work outlines a novel role for PINK/PRKN mediated mitophagy in an 
immune cell-independent context. Clinically, the expression of PRKN is prognostic in 
patient outcome. Decreased PRNK expression is correlated with increased survival [54], 
however increased expression is found with enhanced invasion in tumors [54]. It is 
possible that the role of mitophagy varies dependent on stage or spectrum of mutations 
in CRC. It is also important to consider that PINK1-PRKN independent mechanisms of 
mitophagy exist [55-57]. The use of pharmacological tools to target mitophagy are 
already in development for cancer treatments. In Kras mutant CRC, treatment with 
pharmacological inhibitors of mitochondria, Mito-CP and Mito-Met10, decrease cell 
proliferation [58].  
This work underscores the importance of autophagy in nutrient acquisition in 
colon cancer and the potential for mitophagy inhibition to be used alone or in 





Mouse experiments: For all experiments, male and female mice, 6 to 8-weeks of age 
were used. All mice are a C57BL/6 background. ATG5 TM1a conditional ES cells were 
acquired from Riken and the mice were generated by the University of Michigan 
Transgenic core. Microbiome was normalized for 1-2 weeks prior to experiment initiation 
by combining bedding and distributing evenly among experimental mice.  DSS 
experiments were completed by placing mice on 2.0% DSS in water for 7-days followed 
by a 3-day recovery on regular drinking water. For AOM/DSS experiments, mice were 
injected intraperitoneally (I.P.) with 10mg/kg of AOM. Five days after injection, mice 
were cycled on and off 2.0% DSS in their drinking water for one week followed by a two-
week recovery as previously described [59]. Weights were taken daily. For spontaneous 
tumors (CdxERT2;Apcfl/fl;Atg5fl/fl), mice were injected with a single dose (50mg/kg) of 
tamoxifen. Six weeks later tissue was collected. Tumor burden is a summation of total 
tumor volume per mouse.  
 
Histology and immunofluorescence: Histological analysis was scored by a blinded 
pathologist as previously described [60]. Tissues were collected and fixed in 10% 
formalin for 24-hours followed by embedding in paraffin. 5M sections were stained for 
H&E. Immunofluorescence of Ki67 (1:100; Vector Labs), was completed using antigen 
retrieval in sodium citrate (Tri-sodium citrate 11.4mM, pH 6.0, 0.05% Tween-20) and 
labelled with (Alexa 488, ThermoFisher). Tissue was mounted with ProLong Gold with 
DAPI (Invitrogen). Images were quantified using ImageJ software as percent positive 




RNA isolation and qPCR analysis: RNA was isolated using TRIzol chloroform 
extraction. RNA was reverse transcribed using MMLV reverse transcriptase 
(ThermoFisher). qPCR analysis was done using the listed primers (Table S2.1) and 
Radiant Green qPCR master mix (Alkali Scientific Inc.).  
 
Enteroid Culture: Enteroids were cultured as previously described [28]. Lines 87 and 89 
were cultured in completed LWRN medium. Additional lines (282,584,590,245) were 
cultured in Kerotinocyte Growth Medium (ThermoFisher). Cultures were plated in 
Matrigel (Corning) and allowed to establish for at least 3 days. Following establishment 
cells were treated either with control (Sterile PBS) or chloroquine at 75µg/mL (in PBS) 
for 3 days. Images were taken at 24 and 72-hours post treatment. Measurements were 
completed by normalizing the relative area of an individual enteroid to day 0. All 
measurements were completed by a blinded observer.  
 
Flow Cytometry: Analysis was done using FlowJo software. For Cox8-mCherry-eGFP, 
BioRad Ze5 Cell Analyzer was used. Cells were first sorted for mCherry positivity 
followed by eGFP. Flow cytometry analysis of immune cells was done using the 
Beckman Coulter MoFlo Astrios, immune cells from the colon were isolated by 25mM 
EDTA digestion to remove epithelial cells followed by a 0.5mg/mL collagenase IV 
digestion and were enriched for using a 40% to 70% percoll gradient. Immune cells 
were stained for with CD45 Alexa Fluor 780, 1:200 (eBioscience) , CD4 PECy7 1:300 
(Affymetrix), Cdllc FITC 1:200 (Biolegend), Cdllb APC 1:250 (eBioscience), Ly6C V450 
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1:300 (BD Bioscience), Ly6G PE 1:300 (BD Bioscience), F4/80 BV510 1:100 (BD 
Bioscience), 7AAD Percp Cy 5.5 1:300 (BD Bioscience).  
 
MTT assays: 24-hours following plating a Day 0 reading was taken. Cells were 
incubated for 45 minutes with Thiazolyl Blue Tetrazolium Bromide (Sigma) then 
solubilized with dimethyl sulfoxide. Absorbance was read at 570nm. Following the Day 0 
read, the corresponding treatment and readings were taken every 24-hours for 72-hour 
assay or every other day for 6-day assay. All reads were taken in technical triplicates.  
 
Protein isolation and Western Blotting: All protein samples were separated by SDS-
PAGE and transferred on to nitrocellulose membrane. Antibodies were used as follows. 
TFEB 1:1000 (Bethyl), LC3B 1:1000 (Cell Signaling), ATG5 1:1000 (Cell Signaling), HA-
Tag 1:1000 (Abcam), LAMP1 1:1000 (Cell Signaling), Lamin AC 1:1000 (Active Motif), 
GAPDH 1:1000 (Santa Cruz), β-actin 1:1000 (Proteintech), PRKN 1:1000 (Cell 
Signaling). 
 
Cell lines: All cell lines were cultured in DMEM with 10% fetal bovine serum unless 
otherwise noted. Stable TFEB knockout line was generated using gRNA in Lenticrispr 
V2 ( Feng Zhang; Addgene plasmid 49535) [61] using the guides listed (Table 2.1). 
Constructs for doxycycline inducible shRNA were generated using the Tet-pLKO-puro 
(Dmitri Wiederschain; Addgene plasmid #21915). Plasmids were generated and 
inserted in to a lenti-viral vector for stable transfection. Knockdown was induced using 
200ng/mL of doxycycline for 48-hours. The HCT116 cells used for tracking mitophagy 
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were generated from the pCLBW Cox8-mCherry-EGFP plasmid (David Chan;Addgene 
plasmid #78520). ATG4B mutant expressing cell line was developed by stable 
expression of pmStrawberry-Atg4BC74A (Tamotsu Yoshimori; addgene plasmid #21076). 
We generated the HCT116 LysoIP line using the pLJC5-Tmem192-3xHA (David 
Sabatini ;Addgene plasmid # 102930). Cells were treated chloroquine diphosphate 
(Sigma) and SBI-0206965 (Cayman Chemical) using concentration and time as shown 
in the figure.   
Metabolomics: Polar metabolites were extracted in ice cold 80% methanol on dry ice for 
10 minutes. Proteins and cell debris were precipitated by centrifugation at 13k rpm for 
10 minutes at 4C. Metabolite supernatants were dried on a SpeedVac and submitted for 
steady state metabolomics profiling [62, 63]. An Agilent 1290 Infinity II LC -6470 Triple 
Quadrupole (QqQ) tandem mass spectrometer (MS/MS) system was used. For negative 
ion acquisition, a Waters Acquity UPLC BEH amide column (2.1 x 100mm, 1.7µm) was 
used with the mobile phase (A) consisting of 97% water, 3% methanol 10 mM 
tributylamine, 15 mM acetic acid, and 5 µM Agilent infinity lab deactivator additive and 
mobile phase (B) 10mM tributylamine, 15mM glacial acetic acid, 5 µM Agilent infinity lab 
deactivator additive. Pump A and C deliver buffer A and B respectively. Pump D 
delivers acetronitrile to wash the column at the end of the run. The following gradient 
was used: 0-2.5 min, 100% A at 0.25 mL/min (till 27 min for the analytical run); at 7.5 
min, 80% A; at 13 min 55% A; at 20 min, 1% A and kept to 24.0 min; at 24.05-27 min, 
1%A and 99% D; at 27.05-31.35 min, 1%A and 99% D at 0.8 mL/min flow rate; at 32.25 
to 39.9 min, 100%A at 0.40 mL/min flow rate; at 40 min 100%A, 0.25 mL/min. The 
column was kept at 40 ºC and 3 µL of sample was injected into the LC-MS/MS with a 
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flow rate of 0.2 mL/min. Tuning and calibration of the QqQ was achieved through 
Agilent ESI Low Concentration Tuning Mix. 
The MassHunter Metabolomics Dynamic MRM Database and Method was used for 
target identification. Key parameters of AJS ESI were: Gas Temp: 150 ̊C, Gas Flow 13 
L/min, Nebulizer 45 psi, Sheath Gas Temp 325 ̊C, Sheath Gas Flow 12 L/min, Capillary 
2000 V, Nozzle 500 V. Detector Delta EMV(-) 200. 
The QqQ data were pre-processed with Agilent MassHunter Workstation Quantitative 
Analysis Software (B0700). Each metabolite was median normalized across all samples 
for proper comparisons, statistical analyses, and visualizations among metabolites. The 
statistical significance test was done by a two-tailed t-test with a significance threshold 
level of 0.05. 
Proteomics: Cells were kept in control or media with SerumHI for six days. Cell were 
lysed and lysosomes were isolated as previously described [34] with anti-HA tag 
(Thermo Fisher #88836). Beads were washed twice with TBS-T and twice with PBS. 
The beads were resuspended in 50 mL of 0.1M ammonium bicarbonate buffer (pH~8). 
An overnight digestion with 1 g sequencing grade, modified trypsin was carried out at 
37 C with constant shaking in a Thermomixer. Digestion was stopped by acidification 
and peptides were desalted using SepPak C18 cartridges using manufacturer’s protocol 
(Waters). Samples were completely dried using vacufuge. Resulting peptides were 
dissolved in 8 mL of 0.1% formic acid/2% acetonitrile solution and 2 mL of the peptide 
solution were resolved on a nano-capillary reverse phase column (Acclaim PepMap 
C18, 2µm, 50 cm, ThermoScientific) using a 0.1% formic acid/2% acetonitrile (Buffer A) 
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and 0.1% formic acid/95% acetonitrile (Buffer B) gradient at 300 nL/min over a period of 
180 min (2-25% buffer B in 110 min, 25-40% in 20 min, 40-90% in 5 min followed by 
holding at 90% buffer B for 10 min and requilibration with Buffer A for 30 min). Eluent 
was directly introduced into Q exactive HF mass spectrometer (Thermo Scientific, San 
Jose CA) using an EasySpray source. MS1 scans were acquired at 60K resolution 
(AGC target=3x106; max IT=50 ms). Data-dependent collision induced dissociation 
MS/MS spectra were acquired using Top speed method (3 seconds) following each 
MS1 scan (NCE ~28%; 15K resolution; AGC target 1x105; max IT 45 ms). 
Proteins were identified by searching the MS/MS data against UniProt H Sapiens 
database (20331 entries; downloaded on 12/04/2018) using Proteome Discoverer (v2.1, 
Thermo Scientific). Search parameters included MS1 mass tolerance of 10 ppm and 
fragment tolerance of 0.2 Da; two missed cleavages were allowed; 
carbamidimethylation of cysteine was considered fixed modification and oxidation of 
methionine, deamidation of asparagine and glutamine were considered as potential 
modifications. False discovery rate (FDR) was determined using Percolator and 
proteins/peptides with a FDR of ≤1% were retained for further analysis. Samples were 
normalized to the unbound fraction and relative peptide spectral matches were 
compared between control and SerumHI.   
Statistical Analysis: Statistical analysis was calculated by student’s t-test, one-way, or 
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MMP7 Fw  CAGACTTACCTCGGATCGTAGTGG 
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Figure 2.1 Epithelial loss of autophagy inhibits tumor growth in colitis associated 
cancer model. A. Body weights, B. tumor number, size, and burden, C. quantification 
of Ki67, (non-significant large tumor denoted in orange) D. images of Ki67 staining and  
E. qPCR analysis of cytokines and chemokines following AOM/DSS in colon specific 
Atg5fl/fl  and VillinCre; Atg5fl/fl mice on AOM/DSS * p <0.05, ** p <0.01. Scale bar 200µm 






Figure 2.2 Epithelial loss of autophagy inhibits tumor growth in a sporadic colon 
cancer model. A. Body weights, B. tumor number, size, and burden, C. quantification 
and images of Ki67 stained tumor tissue, D. quantification of Ki67 in normal tissue and 
E. flow cytometry of immune cells in Cdx2-ERT2Cre;Apcfl/fl, and Cdx2-
ERT2Cre;Apcfl/fl;Atg5fl/fl mice. Tumors were assessed at 6-weeks following tamoxifen 
treatment, where flow cytometry was assessed at 2-weeks following tamoxifen 









Figure 2.3 Cell-autonomous inhibition of autophagy inhibits cell growth. A. 
Western blot analysis, B. MTT assay, C. representative images of clonogenic assay and 
D. quantification by blinded observers in stable HCT116 expressing empty vector (EV) 
or two different gRNAs specific for TFEB (Guide 1 and Guide 2). E. Western blot 
analysis, F. MTT assay (EV not shown), G. representative images of clonogenic assay 
and H. quantification of clonogenics by blinded observers in doxycycline inducible 
shRNA specific for TFEB (shRNA 1 and shRNA 2) or EV in HCT116. I. MTT assay (EV 
not shown), J. representative images of clonogenic assay and K. quantification of 
clonogenics by blinded observers in doxycycline inducible shRNA specific for TFEB 
(shRNA 1 and shRNA 2) or EV in SW480. * p <0.05, ** p <0.01 , *** p< 0.001. Error 







Figure 2.4 Pharmacological inhibition of autophagy inhibits CRC growth A. MTT 
assay in colon cancer-derived cell lines (SW480, HCT116 and DLD1) with chloroquine 
treatment. B. Representative images and C. growth quantification of normal and colon 
cancer patient derived enteroids treated with chloroquine for three days. Scale bar 













Figure 2.5 Nutrient stress requires autophagy to maintain cell growth A. Western 
blot and, B. quantification of chloroquine dose to inhibit autophagy in HCT116 and 
SW480.  C. MTT assay, cells were cultured in DMEM with 5% or 10% serum and in 
combination with chloroquine at 2.5µg/mL D. MTT assay, cells were cultured in DMEM 
with normal or SerumHI in combination with chloroquine at 2.5µg/mL. E. 
Supplementation of cells treated with SerumHI and chloroquine with insulin (10nM) in 
HCT116 and SW480 or, F. hEGF (50nM) in HCT116 G. Summary of Snapshot 
Metabolomics of SW480 cells with control or SerumHI or co-treated with vehicle or  
chloroquine. H. Metaboanalyst analysis of metabolites in SerumHI  with chloroquine. * p 








Figure 2.6 CRC cells employ mitophagy under nutrient stress. A. Schematic of 
Cox8-mCherry-GFP flow cytometry. B. Flow cytometry analysis of mitophagy following 
two-day treatment with SerumHI in SW480 and HCT116 cells. C. Western blot 
confirmation of TMEM192-3xHA expressing HCT116 cells. D. Western blot of 
immunoprecipitation of TMEM192-3xHA cells in control or SerumHI. WC- whole cell 
lysate, UB- unbound fraction, IP- bound sample. * represents degraded GAPDH product 
E. Relative change in peptide spectral matches to total and mitochondria specific 











Figure 2.7 Mitophagy is necessary for CRC cell growth A. qPCR analysis of PINK1 
shRNA knockdown and MTT assay (EV shown in Figure S7E) in SW480. B. qPCR 
analysis of PINK1 shRNA knockdown and MTT assay (EV shown in Figure S7E) in 
HCT116. C. qPCR analysis of PINK1 shRNA knockdown and MTT assay (EV shown in 











Figure S2.1 Autophagy loss does not impact acute colitis or Paneth cells in 
sporadic CRC. A. Western blot of Atg5fl/fl  and VillinCre; Atg5fl/fl mice. B. Weights, C. 
colon length, and D.  inflammation score of Atg5fl/fl  and VillinCre; Atg5fl/fl mice following 7-
day DSS with 3 day recovery. E. Panel of cytokines and chemokines following DSS in 
Atg5fl/fl  and VillinCre; Atg5fl/fl. F. H&E staining of control versus DSS treated mice. G. 
Western blot of Tfebfl/fl and Vil-ERT2 mice. H. Weights, I. colon length, and J.  
inflammation score of Tfebfl/fl and Vil-ERT2; Tfebfl/fl  mice following 7-day DSS with 3 day 
recovery. K. Panel of cytokines and chemokines following DSS in Tfebfl/fl and Vil-ERT2. 
L. H&E staining of control versus DSS treated mice. M. qPCR analysis of Paneth cell 
markers in Cdx2-ERT2Cre;Apcfl/fl;Atg5fl/fl  following 6 weeks of tumor formation. N- 















Figure S2.2 ATG4B inhibition reduces CRC growth. A. Analysis of empty vector 
constructs for doxycycline inducible shRNA constructs treated with doxycycline for 6 
days. B. Image of mStrawberry expressing HCT116 ATG4BC74A expressing cells and 
MTT assay of HCT116 ATG4BC74A mutant. B. Representative image and quantification 
of clonogenic assay for ATG4BC74A HCT116 cells. Scale bar 200µm. ** p<0.01. Error 







Figure S2.3 CRC cells are sensitive to pharmacological autophagy inhibition. A. 
MTT assay upon treatment with chloroquine in MC38, HT29, CT26, and RKO. B. MTT 
assay upon treatment with SBI-0206965 in HCT116 cells. C. MTT assay of HCT116 and 
SW480 cells treated for 3-days with chloroquine and measured for 3-days after removal 
of chloroquine. D. Western blot of LC3 expression in patient derived enteroids. * p<0.05, 









Figure S2.4 Nutrient challenge of iron or glucose loss with autophagy inhibition 
does not slow cancer cell growth. A. MTT dose response of chloroquine treatment in 
SW480 and HCT116 cells. B. MTT in iron deplete media and rescue with iron. C. MTT 



















Figure S2.5 ULK inhibition stunts CRC growth. A. MTT of SBI-0206965 (iULK) 
















Figure S2.6 Metabolite modulation under SerumHI and chloroquine does not 
rescue growth A. MTT assay of rescue with amino acids, riboflavin, and dimethyl 






















Figure S2.7 Mitophagy is necessary for CRC cell growth. A.  Western blot analysis 
of PRKN knockdown in HCT116. B. MTT analysis of HCT116 PRKN knockdown (EV 
not shown) C. MTT analysis of RKO PRKN knockdown (EV not shown). D. 
Quantification of clonogenics by blinded observers in doxycycline inducible shRNA for 
PRKN in HCT116, and E. representative image of clonogenic assay. * p< 0.05, **p 












Single Cell Sequencing Reveals Epithelial Sub-Type Activation of Autophagy. 
Abstract 
The tumor environment is comprised of a heterogeneous mix of epithelium, fibroblasts, 
and immune cells that each contribute to tumor growth. Understanding cell specific 
signals in colon cancer will provide information to design targeted therapies for treatment. 
It is known in inflammatory bowel disease that Paneth cells are uniquely impacted by 
autophagy. While it is known that autophagy can modulate tumor growth, the cell type 
specificity of autophagy in colon cancer is not known. Bulk tissue RNA-sequencing can 
mechanistically be informative, but the cell types these transcriptional changes arise from 
are unclear. Here I utilize Seq-Well, a low-cost platform for single-cell transcriptome 
analysis to investigate the complex molecular role of autophagy in colon tumor cells. 
Single-cell RNA sequencing of a sporadic tumor model harboring Apc, p53, and KrasG12D 
mutations uncovered an epithelial sub-type specificity of autophagy. Specifically, 
enterocytes express elevated levels of autophagy activating genes compared to goblet 
and enteroendocrine cells. This work reveals cell type specificity of autophagy activation 
in colon tumor development. Extensive work to investigate cell type changes in autophagy 
during tumor progression will guide the development of therapies that target specific cell 




RNA-sequencing is a powerful technique allowing for the full transcriptomic 
analysis of tissue or cell samples. The Cancer Genome Atlas (TCGA) is a collaborative 
cancer program between the National Cancer Institute and the National Human Genome 
Research Institute. Over the past decade, TCGA has gathered genomic, transcriptomic, 
and protein data that provides clinicians and researchers with tools to better study and 
treat cancer.  Next-generation sequencing methods are also used to determine gene 
signatures and mutation burden that confer with  growth, progression, and metastasis [1, 
2]. Next-generation sequencing used in these publicly available databases typically 
involves sequencing patient biopsies. The tissue includes a combination of epithelial cells, 
fibroblasts, tumor associated immune cells, and tumor stroma. Bulk sequencing 
techniques have uncovered inflammatory signatures that are utilized to identify immune 
changes in tumors [3-6]. Over the past decade, there has been an emergence of the 
importance of tumor cell heterogeneity and stromal contribution to tumor growth [7]. 
Recent literature in colon cancer underscores the importance of cross-talk between tumor 
cells and tumor infiltrating immune cells [8]. Unfortunately, bulk transcriptomics do not 
provide researchers with the tools to understand the impact of immune cell populations 
or different epithelial cells in the colon. The rapid development of single-cell resolution 
techniques affords researchers the ability to evaluate cell type specific changes.   
Methods for capture of single-cell whole-transcriptome (scRNA-seq) data began 
to appear about a decade ago [9]. Single cell sequencing methods have developed to 
investigate genomic, and transcriptomic changes. For transcriptomic analysis, methods 
typically involve isolation of a single cell into a chamber in which reverse transcription and 
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whole transcriptome amplification are carried out. Below is a review of the most commonly 
available methods, Drop-Seq, 10x Genomics Chromium System, and Seq-Well for single-
cell RNA-sequencing.  One of the earliest available methods was the Fluidigm C1 system 
which was previously widely used. Unfortunately, the small cell number output limits this 
technique as new approaches have become available.  
Drop-Seq 
Single-cell sequencing became more available to general users after introduction 
of the Drop-seq system developed by the McCarroll lab in 2015 [10]. Cells are passed 
through a “co-flow” microfluidic device that combines the flow of an oil channel with two 
aqueous solutions to generate nanoliter-sized droplets.  One of the aqueous solutions 
has a microscopic nucleotide coated bead. The beads are generated using split-pool oligo 
methods. Synthesis occurs from 5’ to 3’ where the 3’ end is available for binding of mRNA. 
Each bead contains four regions, (1) an identical sequence on each bead that is used for 
primer binding that is important during the PCR step that will be described later. (2) A 
unique “cell barcode”, (3) a unique molecular identifier (UMI) that is used to differentiate 
duplicate sequences from the PCR step, and (4) an identical region that is used to capture 
polyadenylated mRNA [10]. Barcoding allows the user to identify which reads come from 
an individual cell and following amplification, the original number of transcripts. The 
microfluidic system combines a bead, cell, and lysis solution. Once the cells are lysed, 
the droplets are broken and subjected to reverse transcription. Beads that contain cDNA 
are referred to as STAMPS (single-cell transcriptomes attached to microparticles).  Once 
cDNA is generated, sequencing can be performed. For this method, paired-end 
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sequencing is required to capture the barcode information and transcript information. It is 
estimated that the cost for constructing the system to perform Drop-Seq in the lab is 
around $6,000. One of the major pitfalls to this system is the high cell input number due 
to a capture rate of around 12%. The fluidics system creates a high number of droplets 
containing only a cell or only a bead requiring large input amounts, an approach that is 
not optimal for small or precious samples.  This method is great for individual labs as the 
materials are obtainable but the complex fluidics may cause difficulty in use.  
10x genomics  
The most recent fluidics method available is the 10x Genomics Chromium System 
[11]. The Chromium System works in a similar method to Drop-Seq wherein a single cell 
is captured in what is termed a gel bead in emulsion (GEM). This setup contains a bead 
and a cell in a droplet that contains the reverse transcription reagents in the solution. The 
bead is similarly coated in oligo sequences containing an identical primer sequence. A 
unique cell barcode, and a UMI followed by a poly (dT) region. Similar to Drop-Seq, the 
cells are passed through a microfluidics system and then matched with a bead and placed 
in oil that partitions them into individual cell, bead droplets. Cell capture efficiency is 
significantly improved and ranges around 50%. Unfortunately, the 10x Chromium System 
requires the purchase of the controller system which was introduced at $50,000. This 
limits the use to certain users. In addition to instrumentation, a single sample can range 
around $6,000 dollars making it double the cost of Drop-Seq. A benefit to this approach 
is the time from cell isolation to lysis. Immediately after capture in the GEM cell lysis 
begins. One chip of the 10x system can hold 8 samples, each with a maximum target of 
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10,000 cells per sample. Cost to run the system will vary depending on the institution, at 
the University of Michigan, the cost is approximately $1,800 before sequencing.   
Seq-Well  
One of the major pitfalls to utilizing fluid-based techniques is the high cell number 
required for input in to the system, as well as the requirement to pass potentially sensitive 
cells through a fluidics system. To address these issues, the Seq-well system was 
designed by the Shalek lab at MIT [12]. This system utilizes a micro-well based technique. 
Cells are plated on an array that contains about 86,000 sub-nanoliter wells.  Only 10,000 
cells are needed to load the array. Arrays are loaded via slowly pipetting cell solution over 
the arrays, therefore there is no need for a fluidic system. Cells via gravity fall in to the 
wells that also contain beads as described in the section above. Once cells are collected, 
the array is sealed with a polycarbonate membrane. This membrane is unique in that it 
allows for the diffusion of fluids for lysis and hybridization but traps RNA in the well. When 
the membrane is attached, cells are lysed on the array followed by a hybridization of the 
RNA to the beads. A particular benefit to this method is the availability to gain protein 
information in parallel with sequencing data. Before cells are loaded on to the array, 
proteins may be labelled with conjugated antibodies. Then, the array can be imaged and 
quantified for protein level changes and can be compared to the transcriptomic data. The 
beads are manually removed from the array and are put through a reverse transcription. 
Following reverse transcription, a single stranded DNA digestion is performed. A whole 
genome amplification is done and the sample is removed from the micro-beads and 
submitted for RNA sequencing. A second advantage to this system is the flexibility of use. 
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While functionalizing arrays requires some special equipment, arrays can be shipped to 
any location and the protocol then only requires the arrays, membranes, pipettes, and 
reagents. This is in comparison to the other systems described here which require 
specialized equipment to run.  
The above methods each have unique benefits and pitfalls. When selecting a 
method, the cost, cell type, and efficiency that is desired can go in to choosing a system. 
Another key aspect is the data output from each platform. The number of transcripts and 
genes captured from each cell is essential in gathering enough information to determine 
differences between cell types. Each of these platforms are generally comparable for 
gene and transcript output. The general workflow of each assay is comparable with main 
differences occurring at the cell capture step and whether each step is automated or 
manually completed (Figure 3.1). The output and cost of each platform is outlined in  
Table 3.1.   
When preparing samples for scRNA-seq it is important to consider how isolation 
methods and origin of tissue may impact cell signature. Immediately after excising tissue, 
transcriptional changes and degradation of RNA molecules occurs. Attention to how 
tissues are collected, dissociated, enriched, and processed for single cell capture is 
essential in reducing technical variation [13]. Following generation of a single cell dataset, 
analysis is a significant feature in identifying single-cell variance.   
Analysis of scRNA-seq   
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One of the largest challenges to performing single-cell RNA analysis is parsing the 
data to understand the relationship between cell types and function. With the 
development of better techniques for generating data sets, bioinformaticians are creating 
new ways to perform analysis to visualize data from thousands of cells. Tools are 
available to detect changes between healthy and disease states and predict cell fate 
during development [14]. As of March 2019, around 385 tools for scRNA-seq analysis 
exist [15]. The challenge surrounding single cell analysis is the availability of different 
platforms and standardization of best practices. Below I discuss general processing steps 
involved in the pre-processing of raw reads, data analysis, and general considerations for 
scRNA-seq analysis.  
Sequencing: To appropriately capture sequence from methods such as Drop-Seq 
and Seq-Well, paired-end sequencing must be performed. Read1 can be completed with 
a 26- base pair (bp) read. This 26bp read captures the UMI and cell barcode. A 50bp 
Read2 on the 3’ end captures enough bp’s that can be used to determine the transcript. 
It is important when sequencing to ensure that the average size of the products is greater 
than 420bp. This requirement prevents the potential reading of poly-A tail reads that 
would occur if sequences were shorter. While this sequencing depth was used for this 
dissertation, deeper sequencing can be performed to gather more information from 
individual samples.  
Pre-processing: When sequencing with barcoded beads the reads are first 
organized by their UMI and cellular barcodes. Sequences are then filtered to remove any 
cell or molecular barcodes that are below a base quality threshold. This will prevent 
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matching any reads with the incorrect cell. SMART adapter sequences are trimmed that 
may be present at the 5’ end of the read so they are not present during sequence 
alignment to the genome of interest. While library preparation enriches for sequences 
with longer length, it is possible to obtain sequences with poly-A reads. Any reads with 
more than 6 sequential adenine bases are removed. The library is then aligned to the 
genome and annotated. Any reads that overlap with an exon are tagged and exported for 
analysis.   
Data Analysis: Once the sequences are organized by cell and aligned to the 
genome, an initial quality check is performed. The quality check includes observing the 
number of genes per cell, number of transcripts per cell and mitochondrial genes [16]. 
Cells with high mitochondrial reads or low gene count can be filtered out. High 
mitochondrial reads may indicate that cellular mRNA has leaked out of a damaged 
membrane leaving behind only mtRNA. Cells high in gene counts may be indicative of 
doublets where two cells were captured on one bead. It is important to consider that some 
cell types may be highly proliferative or quiescent which will impact their counts. 
Downstream analysis can be variable based on the user approach and dataset. Analysis 
typically outputs cells in to clusters which groups cells based on the similarity of their gene 
expression. Differential expression between a group of cells and all of the remaining cells 
in the dataset can be used to determine the gene differences in the cluster of interest. 
Cell clustering will vary based on parameters set during analysis [17]. The tool used in 
this dissertation for analysis is Seurat, developed by the Satija lab at MIT [18]. Using 
Seurat, the resolution of clusters can be modified to define more or less clusters. This 
number will vary based on the small versus broad changes that researchers want to 
89 
 
determine in a dataset. With the rise of single-cell sequencing reference databases are 
being generated so that clusters can be annotated using a reference data set rather than 
de novo and determined by known markers [19]. However, due to experimental 
differences, using gene expression from the data is always an important approach. In 
order to reduce technical noise, spike-ins of RNA can be measured and analyzed to 
compensate for variation [20]. Considerations must be made when analyzing changes in 
cell types in differentiation or dynamic models. One approach is using the trajectory 
inference method. This process takes a snap-shot of data and interprets it as a path or 
trajectory [21].  An example of this application is determining the trajectory of sperm 
differentiation [22]. Analysis may also compare changes between treatment groups or 
disease states.  With the emergence of new approaches of analysis there are unique and 
beneficial ways to analyze data. A review of some of these computational approaches 
and methods can be found here [23].  
Single cell analysis in the colon  
The colon is comprised of multiple cell types that play important roles in tissue 
homeostasis. The colon is a highly proliferative organ that constantly regenerates. Stem 
cells are the driving factor that supports this high tissue turnover. Colonic stem cells 
located in the base of the crypts are typically identified by Leucine-rich repeat-containing 
G-protein coupled receptor 5 (LGR5) positivity [24]. They differentiate to generate 
enteroendocrine, enterocytes, goblet cells, and the other diverse cell types of the colon 





These cells control enzyme secretion, secrete peptides, and can control appetite. 
Subclasses of enteroendocrine cells exist based on their secretory products [25]. They 
function in chemosensing and nutrient sensing in the gut and can help to provide signals 
to the brain [25, 26]. Based on the diversity of sub-types of enteroendocrine cells, they 
can be identified by a wide range of markers with a main marker being claudin-4 [27, 28].  
Goblet Cell  
Goblet cells are the primary mucin forming cell of the colon. The secretion of 
mucins provides a protective barrier from the gut associated microbiota. These cells are 
marked by intestinal trefoil factor 3 (TFF3) [29]. Subtypes of mucinous cells exist that add 
complexity to the cell type [30].  
Enterocytes 
Enterocytes are a primary absorptive cell in the colon. Enterocytes are involved in 
processing antigens to present to the immune system. One of the major mechanisms to 
perform this function is through lysosomal degradation [31]. Enterocytes also play a role 
in nutrient and water absorption.   
Differences in the cell types discussed above were examined in the small intestine 
using single cell sequencing [32]. These different cell types can be identified with single 
cell sequencing by known markers. Cells were grouped by Slc12a2, Arg2, TFF3 and 
Defa24 [32]. This study was performed in the small intestine and while the cell types are 
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similar in the large intestine it is important to consider that expression signatures may 
change. 
Little work has been done to assess the transcriptome differences between colonic 
cell types, particularly in colon cancer. Sequencing of 34 colorectal cancer cell lines 
revealed differences in DNA copy number, mRNA, miRNA, and protein analysis between 
different patients [33]. The study provides information about a model system to study 
colon cancer. This system is useful in that you get a gene signature specific to epithelial 
cells. The caveat to this approach is that surrounding supportive cells including fibroblasts 
and immune cells are lost with line establishment. Studies have revealed the 
transcriptional changes between patient derived tissue and their matched cell lines [34]. 
It is important to note that over time, when serial passages are done on cell lines that the 
transcriptional landscape continues to change [34].  
Understanding tumor cell of origin may help researchers to identify potential 
targets to treat colon cancer. In one study of two patient derived samples, normal and 
colon tissue from non-hereditary colon cancer was examined with bulk and single-cell 
whole exome sequencing. Analysis revealed sub-clonal populations with somatic 
mutations [35]. These observations were not available in bulk samples which may hide 
potential hits due to the multiplicity of cell types in the sample. It is important to know that 
these mutational calls were made on 25 single cells. Due to the heterogeneity of the colon, 
certain cell populations may be missed with this small sample pool.  
As highlighted in Chapter 1, understanding the function of autophagy in different 
cell types can provide novel insight on the impact of autophagy in CRC. With bulk 
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sequencing, parsing out signals of autophagy is near to impossible. The single cell 
approach will allow researchers to understand the immune versus epithelial changes in 
autophagy as well as changes between different types of colon cancer cells. Here I utilize 
a sporadic model of colorectal cancer to explore changes in autophagy between colonic 
cell types. Colon cancer patients typically harbor mutations in APC, p53, and KRAS. I 
obtained a triple mutant mouse model that is colon specific (Cdx2-CreERT2; Apcfl/fl; 
Tp53fl/fl;KrasG12D) herein the ‘TripleMut’ to investigate sporadic colon cancer changes. 
When mutations are induced in this model there is a high level of dysplasia present and 
mice typically die within 10 days due to severe dehydration. The dysplasia causes a high 
influx of immune cells and hyper-proliferation of epithelial cells. I chose to utilize this 
model to investigate changes in the autophagy signature in different colonic cell types 











TripleMut mice were induced with tamoxifen at 100mg/kg for 3-days. Due to the 
highly proliferative nature of this model the ratio of epithelial to immune cells would mask 
any immune cell populations and make it difficult to detect them via single-cell 
sequencing. I optimized a protocol to enrich for immune cells. I optimized enrichment of 
immune cells and validated using flow cytometry that I could extract viable, CD45+ 
immune cells (Figure 3.2). Isolated tissue was subjected to single-cell sequencing using 
the Seq-Well platform (Figure 3.3) [12].  
Single cell sequencing revealed both immune and epithelial subtypes (Figure 3.4). 
Populations identified include fibroblasts, enteroendocrine, enterocytes, goblet cells, B-
cells, macrophages, and red blood cells. When the cluster of absorptive cells was 
compared to the enteroendocrine cell types, an increased expression of Itgb4, Itga6, 
Hsp90ab1, Myc was observed (Figure 3.5). Increases in these autophagy genes 
correlate with activated autophagy [36-38]. Similarly, there is a decrease in expression of 
SQSTM1 which correlated with increased autophagy [39]. When comparing absorptive 
cells to goblet cells, there is a decrease in Birc5 suggesting an autophagy increase [40, 
41].                                                                                                                                          
 When compared to bulk RNA-seq from proximal colon of TripleMut mice compared 
to controls, there is no difference observed in these autophagy markers (Figure 3.5). This 
highlights the observed changes that can be found with single cell sequencing that cannot 
be detected with bulk sequencing. However, changes in SQSTM1 can be found 
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compared to control suggesting an overall upregulation of autophagy in highly dysplastic 


















Here I have begun the first investigation to understand the cell type specific 
modulations of autophagy in colon cancer. The TripleMut mice closely model the 
mutational burden seen in human CRC compared to models such as the 
Azoxymethane/Dextran Sulfate Sodium inflammation model. I wanted to investigate both 
immune and epithelial populations in the colon. Due to the highly proliferative nature of 
the TripleMut model, I performed an enrichment for immune cells. This protocol is a 
mixture of of mechanical dissociation, enzymatic digestion, and enrichment via 
centrifugation occur. While I have worked to optimize the shortest method possible, the 
isolation takes approximately 3 hours. This timing and cell stress of dissociation can have 
an impact on the gene signatures observed. For example, while Hsp90ab1 was 
significantly increased in the enterocyte population compared to the enteroendocrine cells 
it was highly expressed in all cell types. This is possibly due to an increase in cell stress 
[42].            
 Unfortunately for this study I did not account for the high amount of red blood cells 
that are present in the sample. The large population present may be due to the high ratio 
of these cells in the sample. Therefore, I further optimized the protocol to include a red 
blood cell lysis step which will enrich further for the cell type of interest. Removal may 
also increase capture of other immune cell types to add diversity and numbers to the 
comparisons. Additionally, the disadvantage to a well system based on gravity is 
differences in cell size. When loading the cells, the standard protocol is to wait 
approximately 10 minutes for cells to fall in to a well. For smaller cells this may take a 
longer period. Optimizing the protocol with this in mind is important for future experiments. 
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The lack of ability to call certain populations may be contributed to the differentiation 
process of cells in the colon. Intermediate cell types include oligomucous cells that 
differentiate to goblet cells, low granule enteroendocrine cells, and midcrypt columnar 
cells that differentiate in to villus columnar cells [43]. Performing analysis with a higher 
resolution may allow for the separation of more clusters that could define these 
intermediate populations. However, it would be best to perform the analysis with a larger 
cell pool to ensure positive identification in smaller populations. For example, analysis of 
a mouse dataset with over 90,000 cells could identify rare populations in 132 cell clusters 
[18].            
 The importance of being able to call intermediate populations is emphasized by 
the development of the Human Cell Atlas which aims to catalog the genomic and 
phenotypic landscape of every cell type in the body. The consortium hopes to define how 
these cells change under developmental and diseased states. Due to the sensitivity of 
identifying each cell type and during different stages of age and health it is important to 
utilize a method that reduces technical variability. Due to the automated and hands-off 
function of the 10x system it has been used to begin generating libraries for the Human 
Cell Atlas. Because multiple users will contribute to the database around the world, a 
highly functionalized system is useful. The pitfalls for Seq-Well and Drop-Seq are the user 
error that can be input.          
 The TripleMut model used here is a valuable tool for future research. For this 
particular experiment mice were induced at a high dose of tamoxifen and euthanized 
almost 10 days after. Mice die at this time point due to hyper-proliferation of the colon. 
This hyper-proliferative phenotype may impact the gene signature discussed here and 
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may not accurately model what is observed in CRC patients. I have identified a low dose 
of tamoxifen (single dose 25mg/kg) that allows mice to survive past 6-weeks and develop 
individual tumors rather than a highly dysplastic colon. In mice that have been induced 
with a low dose of tamoxifen, tumors can be collected at early, middle, and late stages of 
tumor development and single-cell changes can be observed within different cell types. 
An important comparison is also the progressive accumulation of mutations within the 
colon. The TripleMut mice should be simultaneously compared to mice with Apc only, or 
Apc;p53 mutations to better understand how mutation load impacts development. While 
here I have primarily focused on autophagy there is a breadth of information that can be 
acquired from databases generated in these studies. Overall changes in immune markers 
can be investigated to better understand single-cell changes and mice can be challenged 
with different therapeutics to monitor response.  Autophagy models such as the Apcfl/fl 
;Atg5fl/fl model can be used to investigate how loss of autophagy impacts tumor epithelial 
cells.             
 To fully utilize scRNA-seq it is important to know the capabilities of the technique  
when approaching a new question. In cases where researchers may wish to identify new 
areas of focus or ask broad questions, performing a single round of 10x sequencing may 
be beneficial. Typically, a trained technician will be able to process the samples allowing 
for limited troubleshooting and ease of use. However, if a project is aimed at 
understanding timing or spatial changes in a disease or healthy state that simultaneously 
requires multiple samples, a platform where multiple samples can be run in parallel such 
as Seq-Well is more efficacious. Similarly, for the generation of larger datasets, platforms 
such as Drop-Seq and Seq-Well are more desirable due to reduced cost. The available 
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access to a 10x Chromium system, the fluidics for Drop-Seq, or reagents for Seq-Well 
will also impact the choice of platform.         
 Single-cell transcriptomics is a powerful tool that provides insight on a cell by cell 
basis that is not detectible through other methods. Limited information is available for 
scRNA-seq in healthy colon and in diseased states such as CRC. This work only begins 
to uncover differences between colonic cell types in tumor development. Single-cell 
sequencing of different models throughout tumor development will provide insight on 
changes in autophagy. In the future, single-cell sequencing should also be applied to 
patient samples to uncover information not detected in currently available models. Single 
cell resolution will provide in-depth information that can be used in research to improve 












Mice: Mice were housed in standard housing conditions and fed ad libitum. Both male 
and female mice were used. Cdx2-CreERT2 Apcflox p53flox KrasG12D TripleMut mice were 
injected with three doses of 100mg/kg of tamoxifen. Nine days following the first injection, 
mice were euthanized using CO2. Colons are removed and washed in phosphate buffered 
saline.  
Tissue Isolation: Tissue is cut in to 1cm pieces and shook at 150 rotations per minute at 
37ºC in 10mM EDTA. Following incubation, tissues are vortexed to release epithelial cells. 
The tissue is then minced in to 1mm pieces and placed in a collagenase solution 
(0.5mg/mL Collagenase type IV in RPMI) and shook at 250rpm at 37C. Tissues are then 
vortexed and collected for further isolation. The cell pellet is passed through a 100µM 
filter to remove large debris and then mixed in 40% percoll and laid over 70% percoll. The 
cells are spun and the middle, immune cell enriched layer is collected. Cells are then 
passed through a 40µM filter and are ready for array loading.  
Flow Cytometry: Cells were isolated as described above. Cells were stained using CD45 
Alexa Fluor 780, 1:200 (eBioscience), and CalceinAM (1:200). Analysis was performed 
on the MoFlo Astrios (Beckman Coulter). 
RNA isolation and qPCR analysis: RNA was isolated using TRIzol chloroform extraction. 
RNA was reverse transcribed using MMLV reverse transcriptase (ThermoFisher). qPCR 
analysis was done using the listed primers (Table 3.2) and Radiant Green qPCR master 




Array Functionalization: Arrays are functionalized in the following fashion. First, 
Polydimethylsiloxane is poured in to the array mold containing glass slides. Following 
heating at 70C for 2-hours arrays are removed. To functionalize the arrays for use they 
are first plasma cleaned to remove any organic matter from the surface of the array and 
add hydroxyl groups to the surface. Then they are dried and submerged in acetone to 
reduce the surface tension of the array to allow the micro-wells to fill. Arrays are then 
soaked in (3-Aminopropyl) triethoxysilane for silanization which will add amines to the 
hydroxyls. Arrays are then incubated in a mixture of dimethylformamide which acts as a 
solvent with pyridine and p-phenylene diisothiocyanate (PDITC). Because the PDITC 
solution is hydrophobic the next incubation with a chitosan solution prevents the chitosan 
from entering the microwells. Then only the surface of the array is coated. Following 
incubation in a vacuum, arrays are then quenched with an L-aspartic acid, NaCl, and 
Sodium Carbonate solution. This mixture coats the wells to prevent binding of mRNA’s to 
the surface of the array. However, the chitosan coating allows for sealing and unsealing 
of the the polycarbonate membrane has a 10nm pore size which allows for the flow of 
buffers but not RNA transcript.  
Single-cell Library Preparation: Single cell libraries were prepared following the published 
Seq-Well protocol [12]. In summary, 10,000 cells are loaded on to an array and sealed 
with a functionalized polycarbonate membrane. Cells are subjected to lysis and 
hybridization. STAMPS are removed from the array and put through reverse transcription 
overnight. The sample was then put through exonuclease digestion, second strand 
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synthesis, and whole transcriptome amplification. Samples were then tagmented using 
the Illumina NexteraXT kit. 
Sequencing: Samples were sequenced on the Illumina Next-Seq 500 with 26bp Read1 
and 50bp Read 2. Raw data was processed using Picard (Broad Institute, MIT)[44]. Cell 
and molecular barcodes were sorted and any sequences with a phred score of less than 
10 are removed. Any potential extra adapter sequence is removed. PolyA sequences are 
trimmed based on any sequence with more than 6 sequential A sequences. The data set 
was then aligned to the GRCm38 (mm10) genome. After tagging the reads for digital gene 
expression analysis the sample was analyzed using Seurat [45]. First, any genes with an 
average expression less than 5 are removed from analysis. Any cells with less than 150 
genes were filtered out, any cells with higher than 30 percent mitochondrial reads were 
filtered. The sample is then normalized using global-scaling normalization. Then the data 
goes through linear transformation to scale the dataset. Principal component analysis is 
then performed. The elbow method was used to determine significance of PC’s and the 
first 15 PC’s were used in analysis. Clusters are then determined with a resolution of 0.5 
and visualized using t-SNE. Cluster identity was determined by known population 
markers. These include but are not limited to the following. RBC’s (Hbb-bt, Hbb-bs, Hba-
a1), B-cells (Immunoglobulin genes and Mzb1), Monocyte (Macrophages); (Lyz2, Cxcl2, 
Il1β),  Enterocytes (Clca4, Cdh17, Hnf, reduced Tff3), Enteroendocrine (multiple protease 
genes, Reg4,), Goblet (Tff3), Fibroblasts (col3a1, col1a2, col1a1, col14a1, col5a1). Two 
populations were too small to distinguish a cell type and one epithelial population did not 
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Table 3.1 Comparison of popular scRNA-seq platforms. Values for capture 
efficiency, doublet rate, genes/cell, and transcripts/cell are based off of data 
reported by individual platforms. Cost may vary based on sequencing costs and 



















Figure 3.1 Workflow of single-cell sequencing platforms. Overview of automated and 
manual steps of single-cell platforms. RT; reverse transcription. WTA; whole 























Figure 3.2 Validation of viable isolated CD45+ immune cells.  Flow 







Figure 3.3 Functionalized and loaded Seq-Well array. Image of array mold and 
microscopic view of loaded seq-well array. Image of individual well containing 










Figure 3.4 Identification of colon cell types with scRNA-seq. t-SNE plot 
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Figure 3.5 Enterocytes upregulate autophagy in CRC. Expression level 
comparison of significantly different autophagy associated genes between 






Figure 3.6. Autophagy differences are undetectable via bulk RNA 
analysis when compared to normal tissue.  qPCR of autophagy 







Table 3.2 qPCR primers  
Gene Primer 
BIRC5 Fw  GAACCCGATGACAACCCGAT 
BIRC5 Rv  TGGCTCTCTGTCTGTCCAGT 
HSP90AB1 Fw  ATGATCGGGCAGTTTGGTGT 
HSP90AB1 Rv  CACCACTTCCTTGACCCTCC 
ITGa6B Fw  ACCTCAATGCAGATGGGTGG 
ITGA6B Rv  TAAACTGCACCCCCGACTTC 
SQSTM1 Fw  TCTGGGGTAGTGGGTGTCAG 










The tumor microenvironment is a highly complex and heterogeneous mix of cell 
types with pro- and anti-tumor signals. Tumors are comprised of tumor cells, tumor 
associated fibroblasts, immune cells, and extracellular signals from blood supply and 
oxygen availability. A major factor that determines tumor growth is the availability of 
extracellular and intracellular nutrients. In addition to cellular metabolic re-programming 
tumor cells utilize a number of mechanisms to maintain a nutrient pool for proliferation [1-
4]. It is well known in cancer that autophagy can impact not only growth, but resistance 
to drugs, and ability to metastasize [5]. Unfortunately, conflicting literature suggests pro- 
and anti-tumor roles of autophagy in colon cancer [6-9]. 
 This dissertation outlines a novel cell-autonomous role for autophagy in nutrient 
acquisition to promote tumor growth. I have shown that colon cancer cells rely on 
autophagy and specifically employ mitophagy for proliferation. In both sporadic and colitis 
associated cancer models, autophagy loss significantly reduces tumor growth. The 
reduction is not due to microenvironmental factors, rather an intrinsic reliance on 
autophagy. In the overall context of studying autophagy in tumor development, my work 
highlights the significance of understanding internal cellular cues for growth. I discuss 
these findings in the context of available literature to underscore the importance of 
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considering tumor stage and mutational load when studying the impact of autophagy on 
growth or response to therapy.   
Cell-autonomous role of autophagy  
Chapter 1 outlines the conflicting data in the field in which autophagy performs 
both tumor promoting and tumor suppressive roles. Signaling in the tumor environment 
provides non-autonomous cues for tumor progression. Non-cell autonomous cross-talk 
from modulating epithelial autophagy is known to impact the microbiome and immune 
system to modify tumor growth in CRC [10]. Moreover, in pancreatic cancer, cells signal 
to pancreatic stellate cells to induce autophagy to release alanine into the extracellular 
space that can be taken up by cancer cells for growth [4]. However, there is little evidence 
of the cell-autonomous roles of autophagy in colon cancer. I first assessed how loss of 
autophagy through Atg5 deletion decreased tumor number, size, and proliferation in 
sporadic (Cdx2-ERT2Cre;Apcfl/fl;Atg5fl/fl) and colitis (AOM/DSS) associated cancer. The 
sporadic and colitis models do not show changes in immune markers or immune cell 
infiltration. This is possibly due to housing differences and standardizing the microbiome. 
Interestingly, when autophagy was inhibited after tumor development in Vil-ERT2;Atg5fl/fl 
mice, tumor burden was not significantly different with loss of Atg5. These findings 
suggest that autophagy may be important in early tumorigenesis but this observation 
should be studied in more depth (Figure 4.1A&B). Available literature identifies the 
importance of autophagy in preventing tumor development [11]. For example, autophagy 
may prevent DNA damage and tumor initiation [12]. Differences in the stage of tumor 
development may explain discrepancies between studies in CRC. Future work must place 
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an emphasis on understanding the impact of autophagy at different stages in tumor 
development.  
I sought to uncover what cell-autonomous mechanisms inhibited tumor growth. 
Both monolayer and 3D cell culture methods showed a sensitivity to both genetic and 
pharmacological inhibition to autophagy suggesting a reliance on autophagy for survival. 
One study found that HCT116 and SW480 cells do not respond to autophagy inhibition 
similarly in vivo. Contrasting responses may suggest extracellular cues that impact 
autophagy. While this is a possibility, the limitation to this study is the use of the 
chorioallantoic membrane assay to assess growth which may impact cell growth due to 
species cross-reactivity [13].  Overall, cancer derived cell lines and patient-derived 
organoid models in this study showed a cell-autonomous dependency on autophagy, but 
the mechanism remained unknown.   
Available literature on autophagy suggests that the process is utilized for nutrient 
acquisition under stress. However, little is known on exactly what nutrients are targeted 
or used by autophagy in colon cancer. To address this question, I screened cell growth 
in limiting nutrient growth conditions and found that loss of heat labile proteins in 
combination with autophagy inhibition reduced growth. To assess what nutrients were 
dependent on autophagy, I performed metabolomic analysis. The most strongly impacted 
pathway was a decrease in metabolites associated with the TCA cycle. Further work is 
necessary to clearly identify the autophagic dependent nutrients essential to promote cell 
proliferation either individually or in combination. Moreover, analysis of the top hits 
showed a significant decrease in cysteine and methionine metabolism under SerumHI. 
Cysteine is a well-known amino acid that can be oxidized by reactive oxygen species 
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(ROS) [14]. A potential cause of the observed growth inhibition could be due to increased 
ROS due to a reduction in cysteine. I did investigate whether supplementation with N-
acetyl-cysteine, a precursor to cysteine, could rescue growth inhibition. Treating cells with 
N-acetyl-cysteine did not rescue cell growth (data not shown). Similar to cysteine, 
methionine can affect redox reactions and is also known to impact nucleotide metabolism 
in cancer [15].  Because of the high nutrient demand in cancer cells, the requirement of 
several metabolites may be necessary to rescue growth.   
An important limitation to consider when assessing these studies is that the tumor 
microenvironment and the nutrients available are significantly different than that in cell 
culture conditions. For example, cancer cells consume different amounts of glutamine 
based on their in vitro versus in vivo culture [16]. In lung cancer, environmental cysteine 
impacts cells reliance on glutamine and this difference is observed in culture versus in 
the tumor [16]. New tools to eliminate artifacts from cell culture media such as more 
physiological relevant media are being generated to allow for more accurate assessment 
of colon cancer response to available nutrients [17].   
It is important to confirm the cell-autonomous role of autophagy in nutrient 
acquisition in in vivo models. Dietary nutrients contribute to the development of colon 
cancer and have been used as supplement to therapeutic treatments. Diet and nutrient 
interaction in colon tumors is an active area of research. Intermittent fasting and caloric 
restriction can impact tumor growth and progression [18, 19]. Iron is known to increase 
risk of colon cancer [20]. A high fat diet increases the risk of colon cancer development 
[21-23]. Additionally, increase in dietary glucose and fructose also increase risk for colon 
cancer [24, 25]. It is possible that an overabundance of nutrients allows colon cancer cells 
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to bypass the need for autophagy. Under stress and changes in the tumor 
microenvironment, cells upregulate autophagy to acquire nutrients. 
Since nutrient restriction is found to impact tumor growth, I assessed if nutrient 
restriction, in combination with autophagy loss, could synergistically reduce tumor growth. 
To investigate the role of nutrient limitation in combination with autophagy loss I used 
xenograft models where mice were placed on caloric restriction for a week. The mice 
were injected with MC38 mouse adenocarcinoma cell line, 10 days later, injected once 
daily with chloroquine. Mice on 25% caloric restriction with chloroquine did not show a 
significant reduction in tumor growth (Figure 4.2A&B). In many of the previous models 
investigating caloric restriction and tumor growth, mice were calorie restricted significantly 
longer than the present study. Many of the tumors in the present study developed 
ulcerations leading to the shortened timeline. Tumor size did decrease in the caloric 
restriction/autophagy cohort so it is possible that with longer treatment I may observe a 
more robust phenotype. In a second model, the TripleMut mice showed no difference 
after two weeks of chloroquine treatment (Figure 4.3A-D). Dysplastic foci were not 
changed after chloroquine treatment. However, due to the highly proliferative nature at 
two weeks following induction in the TripleMut mice it may be more advantageous to 
perform these experiments following a low dose of tamoxifen.  Similarly, low dose 
tamoxifen should be done in combination with longer treatment of chloroquine. However, 
in order to observe autophagy loss on developed tumors, treatment should be started at 
a timepoint after tumors have developed.  
I have shown a reliance on autophagy and susceptibility to growth inhibition with loss of 
nutrients in SerumHI. It is still unclear how the cell senses this nutrient limitation and 
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signals for autophagy, or mitophagy to be upregulated. A main contributor to nutrient 
sensing in the cell is molecular target of rapamycin (mTOR) [26]. Nutrient signals from 
glucose and amino acids can activate or inhibit mTOR [27]. Autophagy and mTOR have 
a dynamic relationship in which the activity of one impacts the other [28]. The nutrients 
sensed through mTOR may regulate autophagy activation or manipulation of the 
mechanisms between these two pathways may alter normal cell homeostasis [29]. 
Investigation of the cross talk between these pathways may shed light on the mechanisms 
activating autophagy. mTOR regulation should be assessed under different nutrient 
stresses such as SerumHI. When amino acids are abundant, mTOR is activated on the 
lysosomal surface. Loss of available amino acids will inhibit its activation. The acquisition 
of mitochondrial metabolites through mitophagy does impact cell growth as discussed in 
Chapter 2. However, there was an overall increase in peptides present in the lysosome 
under nutrient stress. It is possible that reduced growth is partially attributed to overall 
reduced nutrients and inhibition of mTOR. Another caveat to consider with chloroquine 
treatment is that the mTOR activation on the lysosomal surface may be hindered by the 
pH change induced by chloroquine[30].  
This work primarily focused on the role of autophagy and cell growth. However, 
autophagy is known to modulate metastasis and response to chemotherapeutics. 
Common chemotherapeutics may modulate the activity of autophagy and whether or not 
it enhances or blocks tumor growth. Combination therapy with autophagy inhibition and 
chemotherapy may prove efficacious for some patients. Similarly, dietary modulation in 




Mitophagy in colon cancer  
  Mitophagy has similar conflicting data where it is both pro- and anti-tumorigenic 
[31, 32]. Activation of mitophagy may also be dependent on location within a tumor, either 
the deep tumor or invasive front [33]. The present study defines mitophagy as a pro-tumor 
function in epithelial cells to support proliferation. When PRKN or PINK1 are knocked 
down in colon cancer cell lines, a profound loss of cell growth is observed even in nutrient 
rich conditions. The data suggests that colon cancer cells have adapted to employ 
mitophagy in nutrient rich environments. There are different mechanisms outside of the 
PRKN/PINK1 mediated pathway that induce mitophagy and it is possible that colon 
cancer cells employ alternate mechanisms [34, 35]. Conversely to the data in this thesis, 
one study identified that activation of mitophagy via treatment with Mito-Met10 (a complex 
I inhibitor) can abrogate cell growth [36]. Mito-Met10 can also act on AMPK and cell cycle 
regulators which may explain the decrease in growth compared to mitophagy inhibition 
alone.  
A limitation to this dissertation is the models used to explore mitophagy in colon 
cancer. Due to the differences between in vitro and in vivo models the utilization of a 
tumor model will provide tools to better study this mechanism in tumor development. I 
have crossed a Prknfl/fl mouse with the Cdx2-ERT2Cre; Apcfl/fl model and a Clec16afl/fl  
mouse with the Cdx2-ERT2Cre; Apcfl/fl. Clec16a modulates NRDP1-PRKN regulation. The 
loss of Clec16a enhances expression of PRKN to increase mitophagy [37]. With these 
mice, sporadic tumor development can be studied with the presence or absence of 
mitophagy. Similarly, the Prknfl/fl and Clec16afl/fl mice can be placed on the AOM/DSS 
protocol to observe loss or activation of mitophagy prior to tumor development or after 
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tumors have been developed. These models allow for the assessment of tumor number, 
size, and burden. While I did not observe immune cell changes in the autophagy models 
used in this dissertation, immune cell infiltration should be assessed. Mitophagy is found 
to impact innate immunity in the cell underscoring the importance of investigating different 
facets of mitophagy in the cell [38, 39]. However, since this model utilizes a colon specific 
Cre-recombinase, any changes observed in immune cells will be due to changes in 
cellular cues from epithelial cells. One limitation to these models is that they impact the 
PINK1/PRKN mediated form of mitophagy. When alternate mechanisms of mitophagy in 
colon cancer are identified, mouse models to study these pathways in tumor development 
may be useful.  
  While the Atg5 models I used in this study uncovered a cell-autonomous role for 
autophagy, complete loss of macro-autophagy through Atg5 depletion may impact tumor 
growth differently than that of mitophagy alone. It is possible that a combination of 
nutrients taken up in the lysosome in addition to mitophagy are contributing to the growth 
inhibition. Inducible shRNA for PRKN or PINK1 can be designed to target mouse 
PRKN/PINK1 and stably transfected in to mouse CT26 or MC38 cells. The same cell lines 
can simultaneously be transfected with TMEM192-3xHA. Using these cell lines, 
xenografts of TMEM192-3xHA/PRKN shRNA expressing cells can be induced with or 
without doxycycline and lysosomes can be isolated. Proteomic or metabolomic analysis 
will allow for exploration of changes in lysosomal content following mitophagy inhibition. 




This dissertation uncovered the role of mitophagy in CRC but other selective forms 
of autophagy may be utilized in the cell as discussed in Chapter 1. It is possible that 
mitophagy is primarily employed by specific cell types within the colon epithelium. In colon 
cancer stem cells, resistance to doxyrubicin was attributed to an influx in mitophagy. 
Mitophagy was increased in cancer stem cells compared to the parental cells and led to 
their increased resistance [40]. Mitophagy induction was through a BNIP3 directed 
fashion further underscoring the importance of PRKN-independent mitophagy. In colon 
cancer stem cells, mitochondrial oxidative phosphorylation is increased to maintain their 
proliferative function [41]. Mitophagy may help to maintain the balance of oxidative 
phosphorylation and reduced ROS in these cells. While mitophagy has not been 
investigated in stem cells, future work to understand if basal levels of mitophagy are used 
in this cell population for maintenance may highlight a new clinical target. 
When the cell utilizes autophagy to break down organelles and proteins, the products are 
recycled for cellular use. This dissertation has identified mitochondria as one of the 
degradative substrates to target. However, what these metabolites are used for following 
release in to the cell is not known. Mitochondrial metabolites are known to contribute to 
cellular functions outside of the TCA cycle [42]. It is possible to utilize isotope tracing to 
assess differences in mitochondrial metabolites under nutrient stress [43]. However, this 
will not provide information on where the metabolites are being used in the cell, rather 
what metabolites are being generated.  
 One potential impact of inhibiting macro-autophagy or selective mitophagy is the 
accumulation of dysfunctional mitochondria. The cytotoxicity of these mitochondria may 
reduce cell growth and lead to cell death. Under these conditions it would be important to 
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measure mitochondrial respiration using assays such as Sea Horse developed by Agilent. 
Mitochondria function can also be assessed using immunofluorescence and common 
mitochondrial markers can be compared to measure dysfunctional mitochondria. Further 
investigation on the role of mitophagy is needed in CRC.  
 
Single-cell modulations of autophagy 
The epithelial cell specificity discussed in this dissertation outlines the importance 
of elucidating the mechanistic role of pathways in the hetero-cellular tumor environment. 
While I have identified a cell-autonomous role of autophagy in colon cancer growth, 
autophagy modulation in different colon epithelial cells has not been investigated.  
In a mouse model with loss of Apc, p53, and a mutant KrasG12D I isolated colon 
tissue and performed single-cell sequencing using the Seq-well platform. I identified 
multiple colonic epithelial cell types including secretory and absorptive cells in addition to 
different immune cell types. Within the tumor tissue, increased autophagic gene 
expression was higher in absorptive compared to secretory cells. No changes in immune 
cell-autonomous autophagy was observed. One possibility for the cell type specific 
autophagy expression is that absorptive cells are essential in nutrient uptake from the 
extracellular environment and employ autophagy for breakdown and use. As previously 
discussed, Paneth cell autophagy impacts the intestine in inflammatory bowel disease 
[44]. Moreover, histological analysis determined that goblet cells are found to be enlarged 
following autophagy inhibition in the colon [45]. Single-cell transcriptomic analysis is 
unable to inform researchers about morphological changes which is why this observation 
may not have been found in this study. Single-cell sequencing may be used in 
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combination with new advanced techniques that provide in-depth spatial information [46]. 
Importantly, many of the autophagic changes with single-cell resolution were not 
detectable in bulk RNAseq analysis. When comparing the autophagy signature in whole 
tissue RNA sample, many of the markers were not different when compared to controls. 
This is in part due to the presence of immune cells and the heterogeneous mixture of 
epithelial cells.  
Future studies should aim to understand how autophagy is modulated temporally 
through tumor development. The work in this dissertation and previous literature highlight 
the fluctuation of autophagy in the tumor. While mouse models of colon cancer are an 
invaluable tool for cancer research, often times they do not recapitulate the mutational 
landscape in patients [47]. Common mutations in colon cancer include APC, p53, and 
KRAS among others, but each patient has a unique mutational load. For patients, 
treatment strategies will vary based on mutations, stage, and location of tumor [48]. 
Chapter 1 briefly outlines autophagy mutations present in colon cancer as a prognostic 
tool [49]. Autophagy specific mutations in combination with other common mutations in 
CRC may modulate the impact of how autophagy modulates tumor growth. One example 
of this complexity is that p53 can modulate autophagy by regulating LC3 under starvation 
[50]. No immune differences were found in this study but the known cross-talk between 
immune and tumor epithelial cells emphasizes the need to understand how autophagy 
impacts the tumor as a whole. The limitations from current mouse models, and complexity 
of mutational landscape may be addressed using single-cell sequencing from patient 
derived samples. Seq-well is a cost-effective platform that enables processing of multiple 
samples simultaneously and may be a beneficial tool to explore these questions.  
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Throughout this dissertation I have primarily focused on autophagy at the primary 
tumor sight. When considering tumor stage, it is important to evaluate the metastatic roles 
of this mechanism. Similar to the primary tumor site, autophagy is found to perform pro 
and anti-metastatic roles [51]. Little work has been done specifically in colon cancer to 
address this question.  Single-cell sequencing can be applied to metastatic nodes in colon 
cancer models or from those in patients. Single-cell sequencing may uncover specific cell 
types that metastasize and how autophagy is altered in metastatic versus primary tissue. 
Metastatic models are available to assess these questions in vivo [52]. Understanding 
autophagy in metastatic sites will help guide researchers and clinicians in developing 
therapies and enhancing individualized patient care for those with advance stages of 
disease.   
Therapeutic approaches 
Over the past few decades, interest in targeting autophagy for cancer treatment 
has increased. Therapies directed at these mechanisms may prove effective in reducing 
tumor burden. Hydroxy-chloroquine (HCQ) is currently the only clinically approved 
autophagy inhibitor. Unfortunately, we did not observe significant decrease in tumor 
growth using chloroquine in vivo. This data is consistent with others due to limitations in 
the pharmacokinetics and achieving the proper circulating levels to inhibit autophagy [53, 
54]. The development of more specifically targeted drugs may allow for better treatment 
that can be effective at low doses. I demonstrated that the use of SBI-0206965, a ULK-1 
inhibitor is able to block cell growth. This compound has the potential to be used as a 
more targeted approach of autophagy inhibition following further safety and efficacy 
studies [55]. I utilized a dominant negative ATG4B to inhibit growth, the development of 
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inhibitors NSC185058 and SC377071 which target ATG4B and suppressed 
osteosarcoma growth may also prove beneficial [56]. The functional role of autophagy in 
different cell types is a confounding factor in using therapies targeted toward this 
mechanism. If tools can be utilized to target autophagy in epithelial cells, and not in 
immune cells, it may provide a more efficacious therapy. A promising approach is the 
utilization of nanoparticles. Using nanoparticles, siRNA can be selectively delivered to 
endothelial cells [57]. Nanoparticles can also deliver genes to cells based on cell-specific 
promoters [58]. Drugs can target the tumor via coating nanoparticles with cancer cell 
membrane [59].  I have shown that loss of autophagy in epithelial cells impacts growth 
selectively in tumor cells and does not impact the growth of normal colon cells. Autophagy 
can be specifically targeted in epithelial cells while preventing impact on immune cells 
with this approach as would occur with pharmacological inhibitors. 
This thesis has identified targeting of mitophagy as a potential approach for CRC 
treatment. Pharmacological methods can be used to inhibit mitophagy such as 
mitochondrial division inhibitor (Mdivi1) which inhibits Drp1 activity [60, 61]. There is 
limited bioavailability of potential mitophagy inhibitors. The utilization of siRNA to target 
modulators is a potential approach. While this dissertation primarily focuses on 
PINK1/PRKN mediated mitophagy, other mechanisms of mitophagy may be important to 
acquiring metabolites and targeting these pathways for therapy may be beneficial. If 
tumor cells are adapting to alternate mechanisms the treatments will need to be assessed 
on an individual patient basis.  
 
Final Thoughts  
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This dissertation uncovers a novel role for autophagy in colon cancer growth. This 
work further defines the importance of understanding cell type specific modulations of 
autophagy. While the field of autophagy research in colon cancer is relatively new, the 
potential ability to target this mechanism is efficacious. This data serves as a framework 
for targeting mitophagy as a treatment for colon cancer. Understanding the nutrient 
sensing and mechanisms that activate autophagy in the tumor will inform ways that this 
pathway can be targeted for therapy. Similarly, I have shown the cell-autonomous role of 
autophagy for cell growth but little work has been done in colon cancer on the cell-
autonomous effects on metastasis and response to therapy. Future work may determine 
how autophagy modulation changes during different stages of tumor development and 
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Figure 4.1 Loss of autophagy in late tumor development does not significantly 
reduce tumor growth in colitis associated cancer. A. Weights of mice on AOM/DSS. 



















Figure 4.2 Caloric restriction and pharmacological inhibition of autophagy does not 
significantly reduce growth in xenograft models. A. Quantification of tumor size. B. 













Figure 4.3 Inhibition of autophagy in spontaneous tumor model does not reduce 
low-grade dysplasia at tumor initiation. A. Weights of mice treated with chloroquine. 
B. Dysplasia scoring by blinded pathologist from H&E sections. C. Percent Ki67 positive 
staining. D. Dysplasia scoring of second cohort of mice treated with chloroquine. * p 
<0.05. Error bars represent SEM.  
 
 
 
 
 
 
 
 
 
 
 
 
